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1 Summary 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central 
nervous system (CNS) accompanied by demyelination and axonal loss. Only a 
minority of the demyelinated MS lesions gets remyelinated. In animal models, 
however, remyelination is the default program following immune-mediated or toxic 
demyelination. This thesis aims to find factors regulating remyelination in MS. 
The starting point was autoptic tissue from MS patients. First, different types 
of MS lesions were macrodissected namely, chronic inactive demyelinated lesions 
that had failed to remyelinate, lesions undergoing active demyelination and 
remyelinated lesions. Healthy white matter was used as control tissue. Gene 
expression profiles of these lesions were established using quantitative PCR low 
density arrays. Thereby the focus was on the extracellular matrix (ECM) and on 
factors known to regulate the biology of oligodendrocytes. 
ECM components can regulate oligodendrocyte differentiation and modify 
immune reactions in multiple ways, e.g., by sequestering or displaying growth factors 
and by directly interacting with immune cells and glial cells. The expression of 50 
ECM components and 34 ECM degrading enzymes was measured by qPCR. 
COL1A1, COL3A1, COL5A1 and COL5A2 chains were strongly induced in active 
lesions and even more in chronic inactive lesions. These collagen polypeptide chains 
interact to form collagen types I, III and V, which are grouped as fibrillar collagens. 
Furthermore, two Small Leucine Rich Proteoglycans (SLRPs), biglycan and decorin, 
which can decorate fibrillar collagens, were also strongly induced. Immunostaining 
localized the fibrillar collagens, biglycan, and decorin around blood vessels. These 
ECM molecules were largely seen in the perivascular space closely associated with 
infiltrating immune cells forming a mesh between the endothelium and the astrocytic 
glia limitans. In active lesions collagen V was also seen in the heavily infiltrated brain 
parenchyma. Since these ECM molecules were found largely in the perivascular 
space close to immune cells and hardly in the surrounding parenchyma where 
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oligodendrocyte differentiation takes place, the interaction of these ECM components 
with immune cells was further analysed.  
In vitro experiments revealed that the fibrillar collagens I and III inhibited the 
monocytic production of CCL2 (MCP-1), an inflammatory chemokine thought to be 
involved in the recruitment of immune cells to the inflamed brain. This suggests that 
the induced fibrillar collagens may contribute to the limitation of MS lesions 
expansion by inhibition of the CCL2 production by monocytes. 
The second set of analysed genes comprised 32 factors regulating survival, 
proliferation and/or differentiation of oligodendrocytes and 18 receptors of these 
genes. The key factors for oligodendrocyte differentiation (IGF1, IGF2 and CNTF) 
and oligodendrocyte proliferation (FGF2 and PDGFAA) were still present in 
demyelinated lesions, although their expression ratio was altered. The most striking 
result was the up-regulation of FGF9 in a subset of chronically demyelinated lesions, 
but in none of the remyelinated shadow plaques. The potential functional role of this 
observation was investigated by treating myelinating rat central nervous system 
cultures with exogenous FGF9. In this experimental setting, FGF9 inhibited the 
ability of mature oligodendrocytes to myelinate and ensheath axons. All these data 
suggests that the induction of FGF9 in some chronic MS lesions is one of the 
inhibitory mechanisms accounting for the failure of remyelination. 
Together, this thesis has two main findings: A) Fibrillar collagens, biglycan 
and decorin form a perivascular fibrosis and the fibrillar collagens I and III inhibit 
production of CCL2 by monocytes. Inhibition of CCL2 production by fibrillar 
collagens might contribute to lesion confinement. B) Expression profiles of 
remyelinated MS lesions were established for the first time and thereby, up-regulation 
of FGF9 in demyelinated, but not in remyelinated lesions was revealed. The 
inhibition of myelination in vitro by FGF9 suggests that this is one potential 
mechanism to explain why demyelinated lesions expressing higher FGF9 level fail to 
remyelinate. 
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2 Introduction 
Autoimmune diseases are caused when the body starts producing an 
inappropriate immune response against itself. 5-10% of the general population is 
affected and the pathogenesis is multifactorial, with both inherited and environmental 
components [Invernizzi et al. 2009].   
Autoimmune diseases can be classified in to two types: those that damage 
many organs (systemic autoimmune disease, e.g., systemic lupus erythematosus) and 
those where only a single organ or tissue is damaged by the autoimmune processes 
(localised autoimmune diseases, e.g., multiple sclerosis, type I diabetes and 
Hashimoto’s thyroiditis).  
 
2.1 Multiple sclerosis  
2.1.1 Prominent features  
MS is a chronic inflammatory demyelinating disease of the CNS, which 
typically begins in the second or third decade of life and has a female preponderance 
of 2:1 [Noseworthy et al. 2000]. MS is considered as an autoimmune disease of the 
CNS where the infiltrating immune cells are directed against various components of 
myelin and/or gray matter. MS is a heterogeneous disease with a broad spectrum of 
interindividual differences in clinical presentation, location and frequency of lesions, 
and response to immunosuppressive treatments [Breij et al. 2008]. Typical disabilities 
caused by MS include paralysis, loss of co-ordination, sensory disturbances, and 
impairment of vision and cognitive function [Sospedra et al. 2005]. 
2.1.2 Clinical course 
The clinical course of MS is highly diverse and can be divided primarily into 
four types (Figure 2.1). Relapsing-remitting MS (RRMS): 80-85% of MS patients 
begin with recurrent and reversible neurological deficits. Females are twice likely to 
suffer from RRMS than males. Secondary progressive MS (SPMS): approximately 
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50% of RRMS patients transit into the SP form. SPMS is characterised by disease 
progression with or without relapse and minor remission. Primary progressive MS 
(PPMS): 15% of MS patients have a PP disease course with continuous worsening of 
neurological deficits without clear relapses. Progressive-relapsing MS (PRMS): this is 
the least common form with continuous progression of neurological deficits and 
superimposed  acute relapse but the  period between relapses is characterised by 
continuous progression of symptoms [Trapp et al. 2008; Kieseier et al. 2003].  
               
 
  
Figure 2.1: Clinical courses of multiple sclerosis (modified from Kieseier and Hartung, 2003).  
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2.1.3 Pathology 
MS lesions have three main pathological characteristics, namely, 
inflammation, demyelination with limited remyelination and axonal injury. 
Histopathologically MS is characterized by focal demyelination of white matter with 
a well demarcated hypocellular area characterized by loss of myelin and the 
formation of astrocytic scar and axonal loss. In addition to the classical white matter 
lesion, recent histopathological analysis and modern imaging techniques showed that 
grey matter is also heavily involved in MS. Predilection sites are the optic nerve, the 
periventricular white matter, the cerebellum, the brain stem and the cervical spinal 
cord [Breij et al. 2008]. Lesions are often found around one or several medium sized 
vessels. Inflammatory cells are typically perivascular in location but they also diffuse 
through the damaged BBB and infiltrate the parenchyma. The dominant inflammatory 
cells in  MS lesions are T cells and macrophages with lower and variable contribution 
from B cells and plasma cells [Lassmann 2005]. Both CD4 and CD8 positive T cells 
have been observed in active lesions [Traugott et al. 1983], and clonal expansion of 
CD8 positive T cells has also been documented in MS lesions [Babbe et al. 2000; 
Junker et al. 2007]. Axonal damage is an integral and early pathological feature of 
MS lesions [Ferguson et al. 1997]. Axonal transection was also observed in 
demyelinating lesions and was more in inactive lesions compared to the active lesions 
[Trapp et al. 1998]. 
MS lesions can be divided into different stages based on different parameters, 
including inflammatory cells, glial cells, axonal loss and myelin staining.  These 
stages are Active demyelinating lesions which contain abundant macrophages with 
myelin degradation products (luxol fast blue or Oil Red O positive) either throughout 
the lesion or as a broad rim around the lesion edge. Inactive demyelinated lesions 
which can be sharply demarcated from the normal appearing white matter and are 
without a rim of microglial activation and do not contain any luxol fast blue or Oil 
Red O positive macrophages.  
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The active demyelinating lesions can be further divided into four different 
patterns, based on the distribution of myelin loss, the plaque geography and 
extension, the pattern of oligodendrocyte destruction, immunoglobulin deposition and 
complement activation [Lucchinetti et al. 1999]. One common hallmark among all 
the four patterns of demyelination is the presence of inflammatory infiltrates like T 
cells, macrophages and microglia. It should be noted that these patterns of 
classification are controversial. 
The four patterns are: Pattern I (macrophage-associated demyelination): 
lesions are perivenously distributed and are characterised by a sharply demarcated 
lesion edge. There is a T cell mediated inflammation with macrophage and microglia 
activation. Activated macrophages and microglia are associated with degenerating 
myelin and demyelination assumably induced by macrophage toxins. This pattern 
closely resembles the myelin destruction in mouse models of experimental 
autoimmune encephalomyelitis (EAE), where toxic products of activated 
macrophages are responsible for myelin destruction. Pattern II (antibody-mediated 
demyelination): similar to pattern I. There is T cell mediated inflammation with 
macrophage and microglia activation and deposition of immunoglobulin’s and 
activated complements at sites of active myelin destruction. Demyelination might be 
induced by complement mediated lysis of antibody targeted myelin. This pattern is 
reflected in models of EAE where the disease is induced by sensitization with myelin 
oligodendrocyte glycoprotein (MOG) and where demyelination is induced by 
encephalitogenic T cells and demyelinating anti-MOG antibodies. Pattern III (distal 
oligodendrogliopathy associated demyelination): these lesions are not centered by 
veins and venules. The lesion border is ill defined, with a diffused spread into the 
surrounding white matter.  There is a T cell mediated inflammation with macrophage 
and microglia activation along with small vessel vasculitis and secondary ischemic 
damage of the white matter. Preservation of a rim of myelin is frequently observed 
around inflamed blood vessels with in a demyelinated plaque. The striking feature in 
pattern III lesions is the preferential loss of myelin associated glycoprotein (MAG), 
while other myelin proteins like proteolipid protein (PLP), myelin basic protein 
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(MBP) and 2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNP) are still present 
within the partially damaged myelin sheaths. Demyelination is caused by 
degeneration of distal oligodendrocyte processes followed by oligodendrocyte 
apoptosis. This pattern is not reflected in animal models of MS. Pattern IV (primary 
oligodendrocyte degeneration mediated demyelination): these lesions are also 
similar to pattern I. there is a T cell mediated inflammation with macrophage and 
microglia activation. Demyelination is induced by macrophage toxins on the 
background of metabolically impaired oligodendrocytes. Oligodendrocyte 
degeneration is observed in a small rim of periplaque white matter, adjacent to the 
zone of active myelin destruction. This pattern of demyelination is very infrequent in 
the MS population and is restricted to a subset of patients with PPMS [Lassmann et 
al. 2001; Lucchinetti et al. 2000]. 
 
2.2 Remyelination 
Besides the destructive mechanism in MS, endogenous repair mechanisms 
which contribute to axonal protection called ‘remyelination’ occurs [Irvine et al. 
2008]. Remyelination has been described as a frequent phenomenon in acute or early 
MS lesions [Lassmann 1983; Raine et al. 1993]. Remyelinated lesions are also 
present in chronic MS lesions [Prineas et al. 1979]. Frequently, remyelination is 
found as a rim at the border of chronic MS lesions. Completely remyelinated lesions 
called shadow plaques are less frequently observed (Figure 2.2). It has been 
suggested that remyelination is a transient phenomenon [Frohman et al. 2006] and 
that remyelinated shadow plaques might become affected with the new bouts of 
demyelination [Prineas et al. 1993]. Extensive remyelination is found not only in 
patients with RRMS, but also in a subset of patients with progressive disease. Older 
age at death and longer disease duration is associated with significantly more 
remyelinated lesions (shadow plaques) or remyelinated lesion rim (lesion areas) 
[Patrikios et al. 2006]. Location of the lesion also influences the likelihood of 
remyelination, 44.4% of  cortical lesions in contrast to 22% of periventricular lesions 
showed marked remyelination [Goldschmidt et al. 2009]. 
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Figure 2.2: Pathology of MS lesion: MS brain stained with Luxol Fast Blue (LFB), which stains 
myelin blue. Green arrows show demyelinated lesions and red arrows indicate shadow plaques 
(completely remyelinated lesions) (modified from Adams C.W.M, 1989, Wolfe Medical Publications, 
London.). 
 
2.2.1 Why is remyelination important? 
In the first place, remyelination is important for restoring saltatory action 
potential. The second key function of remyelination in MS is axonal survival [Irvine 
et al. 2008]. Remyelination protects neurons by providing trophic support to promote 
survival of underlying neurons [Wilkins et al. 2003; Franklin et al. 2008b]. 
Demyelination undoubtedly represents a major part of the pathology of MS, 
but in the recent years, it has become increasingly apparent that there is also a 
substantial axonal and neuronal loss. Hence, permanent neurological dysfunction 
observed in MS has been attributed to demyelination not to axonal injury, and is the 
major cause of the chronic progressive disease. Demyelinated axons are especially 
vulnerable to damage during the acute phase and possibly also prone to damage and 
atrophy during the chronic phase of MS [Ferguson et al. 1997; Trapp et al. 1998]. 
The cause for such axonal atrophy is unclear, but demyelination may predispose 
axons to secondary injury by (a) multiple molecular cytotoxicity mechanisms, 
including ion channel dysfunction and mitochondrial damage, or (b) failure of local 
target derived neurotrophic support for myelinating oligodendrocytes. 
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2.2.2 How does remyelination occur? 
Remyelination involves the generation of new mature oligodendrocytes. Data 
based largely on rodent studies show that remyelination is mediated by new 
oligodendrocytes derived from a population of adult CNS stem/precursor cells, 
referred to as adult oligodendrocyte precursors (OPCs) [Ffrench-Constant et al. 1986; 
Dawson et al. 2003]. OPCs are proliferating cells, which are widely spread through 
the CNS and are found in both white matter and grey matter at a density similar to 
that of microglia (5-8% of the adult CNS cell population) [Polito et al. 2005; Levine 
et al. 2001]. These OPCs are NG2 (a chondroitin sulfate proteoglycan) and PDGFRα 
(platelet-derived growth factor receptor alpha) positive. The process of remyelination 
occurs in two phases (a) Recruitment phase, during which OPCs are recruited to the 
demyelinated area and proliferate. (b) Differentiation phase, in which the newly 
recruited OPCs differentiate into premyelinating oligodendrocytes which contact 
demyelinated axons and differentiate into mature myelin producing oligodendrocytes 
[Chari 2007]. Remyelination  results in a thinner myelin sheath and shorter internodes 
than it would be expected for a given diameter of  the axon [Franklin et al. 2008a]. 
 
2.2.3 Why does remyelination fail frequently? 
Remyelination is a default process in most animal models but fails frequently 
in MS. Remyelination could fail because of a primary deficiency in the  precursor 
cells, a failure of precursor cell recruitment, or a failure of precursor cell 
differentiation and maturation [Franklin 2002]. Some of the MS lesions fail to 
remyelinate not because of the shortage of available precursor cells but because of a 
failure of OPC recruitment, involving proliferation, migration to and repopulation of 
demyelinated areas. This might be explained by either the fact that some MS patients 
generate  antibodies against the OPC expressed antigen NG2 [Niehaus et al. 2000],or 
by  disturbances in the local expression of the OPC migration guidance cues 
semaphorin 3A and 3F [Williams et al. 2007]. Several sets of observations indicated 
that differentiation and maturation  of oligodendrocytes is most vulnerable to the 
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failure of remyelination in MS. Analyses of MS lesions show presence of 
premyelinating oligodendrocytes in chronic MS lesions [Chang et al. 2002]. Even 
though the density of OPCs in the chronic lesions on average is lower than in normal 
white matter, it also can be as high as in normal white matter and in remyelinated 
lesions. This adds to the view that the availability of OPCs is not a limiting factor for 
remyelination, but rather the differentiation of the OPCs is disturbed [Kuhlmann et al. 
2008]. Several factors can be attributed to this failure of differentiation. Namely, re-
expression of  the Notch-jagged signalling pathway [Wang et al. 1998; John et al. 
2002], up-regulation of the  extracellular matrix protein hyaluronan [Back et al. 2005] 
in chronic demyelinated MS lesions and expression of polysialylated neural cell 
adhesion molecule (PSA-NCAM) by demyelinated axons, by which these axons send 
negative signals to oligodendrocytes  and thereby inhibit remyelination [Charles et al. 
2002; Charles et al. 2000]. 
 
2.2.4 How can remyelination be enhanced?   
Currently there are no specific clinical therapies available, which promote 
remyelination. However, there are two therapies in development, which are preceding 
towards phase I clinical trials. One is anti-LINGO therapy by Biogen Idec 
(http://www.biogenidec.com/site/pipeline.html) [Rudick et al. 2008; Mi et al. 2007] 
and the other is the application of recombinant human IgM which is currently 
developed at the Mayo clinic 
(http://www.mayoclinic.org/medicalprofs/remyelination.html) [Warrington et al. 
2000; Warrington et al. 2008; Warrington et al. 2007]. Both of these potential 
therapies have been shown to promote remyelination in various animal models.  
Furthermore, there are two therapeutic approaches currently being tested in 
animal models of Demyelination. These are cell replacement by transplantation 
(exogenous therapy) and promotion of repair by the resident stem- and precursor- cell 
populations in the adult CNS (endogenous repair). The effectiveness of any therapy 
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promoting remyelination will depends on the ability to suppress the effect of any 
ongoing disease process on the new oligodendrocytes.  
Different cell types including primary OPCs, Schwann cells, olfactory 
ensheathing cells, neural stem cell and embryonic stem cell derived glial precursors 
have been shown to generate myelinating cells following transplantation [Franklin et 
al. 2008a]. As remyelination can be completed and as the cells that are responsible for 
remyelination are abundant throughout the adult CNS, an attractive approach is to 
target the endogenous cells for remyelination. This approach is completely based on 
the understanding of the mechanisms of remyelination and failure of remyelination. 
The pro-recruitment therapies may not promote remyelination where the primary 
problem is OPC differentiation and vice versa [Franklin 2002; Franklin et al. 2008a]. 
 
2.3 Extra cellular matrix in multiple sclerosis 
 
The ECM in MS lesions potentially affects myelination/remyelination and 
immune cell function. Hyaluronan, a proteoglycan is up–regulated in inactive 
demyelinated lesions and inhibits oligodendrocyte maturation, thereby inhibiting 
remyelination of the chronic demyelinated lesions [Back et al. 2005].  In addition, it 
was recently shown in EAE models that laminin α5 directly inhibited integrin 
mediated migration of T lymphocytes, resulting in marked and selective reduction of 
T lymphocyte infiltration into the brain, reduced disease susceptibility and severity 
[Wu et al. 2009]. In MS the interactions between infiltrating immune cells and the 
CNS environment determine the fate of the MS lesion.  
ECM is referred to as the ground substance found in the interstitial spaces of 
all organs and organ systems providing support to the cells. A substantial volume 
(1/5th) of the brain is filled with ECM [Bignami et al. 1993; Rutka et al. 1988]. Under 
normal conditions, the ECM of the CNS is unique in its composition, with smaller 
amounts of fibrous proteins (collagens, laminin-1 and fibronectin), and higher 
amounts of linear polysaccharides (glycosaminoglycans (GAGs) such as hyaluronan, 
chondroitin sulphate and heparin sulfate) [Novak et al. 2000; Rauch 2004; Viapiano 
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et al. 2006]. Brain endothelial cells, astrocytes, neurons and microglia can synthesise 
and secrete several ECM proteins [Tilling et al. 2002; Van der Laan et al. 1997a]. 
The ECM has traditionally been considered to play predominantly a structural 
role, but in the past few years various other features of the ECM in the CNS have 
emerged. During the development ,the ECM is involved in the migration, maturation, 
differentiation and survival of neurons [Oohira et al. 2000]. In adults, the ECM 
provides physical support for the brain resident cells and regulates ionic and 
nutritional homeostasis [Bandtlow et al. 2000; Rauch 2004; Yamaguchi 2000]. 
Furthermore, the ECM binds to both growth promoting and growth inhibitory factors 
and many times acts as a reservoir of these factors [Saksela et al. 1990; Deepa et al. 
2004; Deepa et al. 2002; Kawashima et al. 2002; Kantor et al. 2004] . 
A complex alteration in the CNS ECM occurs during the disease course of 
MS, expression of both the parenchymal and the basement membrane related ECM 
proteins are altered. The expression of the chondroitin and/or dermatan sulphate 
proteoglycans in the active MS lesions is altered; in the same lesions foamy 
macrophages accumulated these proteoglycans along with myelin breakdown 
products [Sobel et al. 2001]. Loss of tenascin-C and –R immunoreactivity is seen in 
acute MS lesions [Gutowski et al. 1999]. Among the basement membrane proteins 
vitronectin immunoreactivity was enhanced in the blood vessel walls of active MS 
lesions, at the border of chronic active lesions and on few hypertrophic astrocytes 
[Sobel et al. 1995]. Alterations in the expression of different laminin isoforms in the 
basement membrane of inflamed blood vessels and increased immunoreactivity for 
fibronectin and collagen IV was observed on immune cells [Esiri et al. 1991; Sobel et 
al. 1989; Van et al. 2005]. EAE experiments have elaborated decisive roles of the 
basement membranes and their laminins for immune cell entry into the CNS 
[Agrawal et al. 2006; Sixt et al. 2001; Wu et al. 2009].  
2.3.1 Collagens  
In addition to the ECM components mentioned above collagens and SLRPs 
are also important components of the ECM. Collagens are a large family of triple 
Introduction  13 
 
helical proteins that are widespread throughout the body. They are important for a 
broad range of functions, including tissue scaffolding, cell adhesion, cell migration, 
tissue morphogenesis and tissue repair. Collagens are the best known as the principle 
tensile element of vertebrate tissues such as tendon, cartilage, bone, and skin where 
collagens are present as elongated fibrils in the ECM. Collagens contain three 
polypeptide chains. Each polypeptide chain contains a repeating Gly-X-Y triplet in 
which glycine residue occupies every third position and the position X and Y are 
occupied by proline and 4-hydroxyproline, respectively. The three polypeptide chains 
are held together by interchain hydrogen bonds [Kadler et al. 2007]. The human 
genome codes for at least 43 distinct collagen chains that are assembled in to 28 
collagen types [Myllyharju et al. 2004]. Collagens can be mainly divided into two 
groups, the fibril forming and the non fibril collagens. Fibrillar collagens include 
collagen I, II, III, V, XI, XXIV, and XXVII. Fibrillar collagen chains are associated 
as homotrimers (e.g. collagen II, III), heterotrimers (e.g. collagen XI) or both (e.g. 
collagen I, V) [Ricard-Blum et al. 2005]. 
2.3.2 Small leucine rich proteoglycans  
Small leucine rich proteoglycans (SLRPs) belongs to a gene class whose 
structural hallmark is the presence of tandem arrays of leucine-rich repeats flanked by 
two cysteine-rich regions with highly conserved spacings. The SLRP gene family 
includes 17 genes which can be classified into five distinct groups based on several 
parameters including conservation and homology at the protein and genomic levels, 
the presence of characteristic N-terminal Cys-rich clusters with defined spacing and 
chromosomal organization. Members of SLRPs are decorin, biglycan, fibromodulin 
and lumican. These proteoglycans are tissue organizers, orienting and ordering 
collagen fibrils during development and in pathological processes such as wound 
healing and tissue repair. They can also interact with soluble growth factors, modulate 
their functional activity and availability, and bind to cell surface receptors, thereby 
affecting different cellular processes [Schaefer et al. 2008; Iozzo 1997; Iozzo 1999].  
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2.4 Factors regulating remyelination 
 
The procurement of growth factor–mediated trophic support for 
oligodendrocytes and their progenitors is one of the potential approaches to stimulate 
endogenous remyelination. A number of growth factors have been identified which 
alone or in combination, promote proliferation, survival and differentiation of 
oligodendrocyte progenitor cells. These include members of the neurotrophin family, 
insulin-like growth factors (IGFs), platelet-derived growth factors (PDGFs), 
fibroblast growth factors (FGFs), cytokines of interleukin-6 (IL-6) family and 
neuregulins (NRGs). 
 
2.4.1 Neurotrophins 
Neurotrophins are a family of growth factors critical for the development and 
functioning of the nervous system. They include: nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and NT-4/5. These 
neurotrophins  bind to specific tyrosine kinase receptors (Trks): NGF binds to TrkA, 
BDNF and NT-4/5 bind to TrkB and NT-3 to TrkC. NT-3 regulates the survival 
proliferation and differentiation of OPCs in vitro, while NGF and BDNF have been 
shown to protect oligodendrocytes from death induced in vitro by the 
proinflammatory cytokine TNFα and in vivo by spinal cord injury, respectively 
[Heinrich et al. 1999; Bertollini et al. 1997; Barres et al. 1994; Kerschensteiner et al. 
2003]. BDNF and its high affinity receptor TrkB  are markedly increased in MS 
lesions [Stadelmann et al. 2002]. 
 
2.4.2 Insulin-like growth factor-I 
A role for IGF-I in the proliferation and differentiation of OPCs has been 
proposed based on its effects on developmental myelination and its enhanced 
expression in experimental model of demyelination and MS lesions [Gveric et al. 
1999; Yao et al. 1995]. IGF-I has been shown to protect oligodendrocytes from TNFα 
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induced injury [Ye et al. 1999]. Administration of IGF-I in EAE reduced lesion 
extension and promoted remyelination in one study [Liu et al. 1995], but others did 
not support the protective role of IGF-I in EAE models  [Genoud et al. 2005; 
Cannella et al. 2000]. A recent study in humans has shown that there is no statistical 
significant difference in the levels of IGF-I in serum and CSF of MS patients and 
controls [Poljakovic et al. 2006]. 
 
2.4.3 Platelet-derived growth factor  
Extensive studies have been done on the effects of PDGFs on CNS 
myelination during development. The PDGF family of growth factor is composed of 
four different polypeptide chains encoded by four different genes. The four PDGF 
chains assemble into disulphide bonded dimers via homo or heterodimerization and 
five different dimeric isoforms have been described; PDGF-AA, PDGF-AB, PDGF-
BB, PDGF-CC, PDGF-DD. PDGF-AA, PDGF-AB, PDGF-BB and PDGF-CC can  
bind to and activate PDGFRα, while PDGF-BB and PDGF-DD can specifically bind 
to and activate PDGFRβ [Fredriksson et al. 2004]. PDGF-AA can act as a survival 
factor during oligodendrocyte development [Gard et al. 1995]. PDGF-AA also has an 
important pro-migratory and mitogenic effect on oligodendrocyte progenitors. A 
correlation between cerebral PDGF levels and accumulation of OPCs following 
experimental demyelination has been established, supporting a role for PDGF-A in 
the recruitment of these cells into lesion area [Franklin 2002; Woodruff et al. 2004]. 
 
2.4.4 IL-6 family 
Neuropoietins comprise a family of pleiotropic cytokines with implications in 
development, inflammation, tissue injury and healing processes. Well studied 
members of this group are IL-6, ciliary neurotrophic factor (CNTF), and leukemia 
inhibitory factor (LIF) for their role in oligodendrocyte development and 
inflammatory demyelinating disease [Aloisi 2003].In addition to their effects on 
neuronal survival and differentiation, LIF and CNTF  also act on OPCs by promoting 
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their survival, proliferation and maturation. In vitro studies showed that both LIF and 
CNTF protect oligodendrocytes from death induced by the proinflammatory 
cytokines TNFα and IFNγ [Vanderlocht et al. 2006; Linker et al. 2002]. In an EAE 
model, exogenously administered LIF ameliorated disease and endogenous LIF had a 
role in limiting oligodendrocyte loss during the disease [Butzkueven et al. 2002]. 
 
2.4.5 Fibroblast growth factors 
FGFs constitute one of the largest family of growth and differentiation factors 
for cells of mesodermal and neuroectodermal origin. They participate in many 
developmental and repair processes. This family comprises of 23 FGF members, of 
which 10 have been identified in brain. The prototypic members are acidic FGF 
(aFGF or FGF1) and basic FGF (bFGF or FGF2). In the CNS, FGFs are widely 
expressed. FGF2 is primarily synthesized by astrocytes and FGF5, -8 and -9 are 
primarily synthesized by neurons [Reuss et al. 2003]. Experimental results suggest a 
putative role for FGF2 in the pathogenesis of demyelination and remyelination in 
EAE [Messersmith et al. 2000]. FGF2, expressed by astrocytes and microglias, has 
been shown to be a potent mitogen for OPCs [Frost et al. 2003]. 
  Recent in vitro findings indicate that FGF2 has differential effects on cells of 
the early and late oligodendrocyte lineage: at first dramatically expanding their 
population throughout premyelinating and myelinating cells, but subsequently 
causing the loss of these previously generated cells [Butt et al. 2005]. Recently it has 
been shown that FGF2 levels are elevated  in the CSF of  MS patients [Sarchielli et 
al. 2008]. 
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3 Objectives and strategy  
Focal demyelination with limited remyelination is one of the hallmarks of 
multiple sclerosis. Why most lesions fail to remyelinate is unclear, as the CNS 
contains an endogenous repair mechanism that normally acts to ensure rapid and 
essentially complete remyelination. The aim of this thesis was to get insight into 
possible mechanisms explaining the frequent failure of remyelination in MS lesions. 
This failure might be due to alterations of the extracellular matrix and/or alterations 
of factors mediating growth, survival and differentiation of oligodendrocytes. 
 
This thesis involved the following steps: 
1. Identification of different types of MS lesions: demyelinated active, demyelinated 
chronic inactive and remyelinated lesions in autoptic tissue (in collaboration with 
Prof. Hans Lassmann). 
2. Dissection of these lesions, and preparation of lesion specific RNA and cDNA, and 
testing for usefulness of transcript quantification. 
3. Determining the expression profiles of MS lesions by quantitative PCR, with focus 
on ECM components, ECM degrading enzymes, growth and/or survival factors for 
oligodendrocytes and their receptors. 
4. Localization of the up-regulated ECM molecules by immunohistochemistry in MS 
lesions. 
5. Performing in vitro experiments based on the results of 4. Studying effects of 
induced ECM molecules on immune cells.  
6. Studying the effects of potential inhibitors of remyelination in an in vitro 
myelination assay (co-operation with Prof. Chris. Linington). 
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4 Materials and Methods 
4.1 Materials  
4.1.1 Antibodies 
 
 
Primary antibodies 
 
 
Secondary antibodies 
 
 
 
 
 
Tertiary antibodies 
PAP (peroxidase anti peroxidase) rabbit -DAKO Z0113 
PAP (peroxidase anti peroxidase) mouse -DAKO P0850 
Antigen Specificity Species Clonality Source Catalogue No. 
Biglycan human rabbit polyclonal kind gift from 
Prof. Larry Fisher 
 
CD31 human sheep polyclonal R&D AF806 
CD68 human mouse monoclonal DAKO N1576 
Collagen I human mouse monoclonal Abcam ab6308 
Collagen III human mouse monoclonal Abcam Ab6310 
Collagen V human rabbit polyclonal AbD serotec 2150-0180 
Decorin human mouse monoclonal R&D MAB143 
Decorin human rabbit polyclonal kind gift from 
Prof. Larry Fisher 
 
FGF9 human mouse monoclonal Santa Cruz sc-8413 
FGF9 human goat polyclonal R&D AF-273-NA 
FGFR2 human rabbit polyclonal Santa Cruz ab5476 
FGFR3 human rabbit polyclonal Santa Cruz sc-123 
FGFR3 human mouse monoclonal Santa Cruz sc-13121 
GFAP human mouse monoclonal Molecular Probes 131-17719 
Specificity Species Label Source Catalogue No. 
mouse donkey alexa-488 Molecular Probes A21202 
rabbit donkey alexa-594 Molecular Probes A21207 
sheep donkey alexa-488 Molecular Probes A11015 
mouse rabbit none DAKO Z0259 
rabbit swine none DAKO Z0196 
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4.1.2 Buffers and reagents 
 
4% Paraformaldehyde (PFA) 
       4% PFA in PBS pH 7.4 
    
Cell culture medium 
       RPMI 1640 or DMEM 
      1% Pen-Strep (10,000 U/ml penicillin G and 10,000 µg/ml streptomycin) 
      10% fetal calf serum (FCS) 
 
Citrate buffer 
       Solution A: 0.1 M citric acid solution in PBS pH 7.4 
       Solution B: 0.1 M sodium citrate solution in PBS pH 7.4 
       Mix 9 ml of Sol A + 41 ml of Sol B + 450 ml PBS pH 6  
  
Lithium carbonate 
     0.1% lithium carbonate in distilled water. (Light sensitive, store in brown bottle). 
 
 Luxol fast blue (LFB 0.1%) 
      0.1 grams of LFB in 100 ml 96% ethanol   
      0.5 ml 10% acetic acid added to the above solution 
 
MACS buffer 
       0.2 mM EDTA, 2% FCS in PBS pH 7.4, 0.2 µm filter sterilized 
 
Reagent diluent (ELISA) 
      1% BSA in PBS pH 7.4, 0.2 µm filter sterilized 
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Schiff’s reagent 
     10 ml HCl 
     5 ml 10% sodium pyrosulfite 
     85 ml distilled water 
     0.2 gm pararosanilin 
     Allow the solution to stand O/N and then filter through 0.2-0.3 grams of activated 
charcoal         
 
Schiff’s wash solution 
     10 ml 10% sodium pyrosulfite 
     10 ml HCl 
     200 ml distilled water 
 
Wash buffer (ELISA) 
      0.05% Tween 20 in PBS pH 7.4 
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4.1.3 Patients and tissue samples 
A total of 19 snap-frozen MS lesions and 6 control white matter from 13 MS 
subjects and 4 control subjects without clinical or histological evidence of brain 
disease were analysed for transcript expression (Table 4.1). Three of the MS 
specimens were obtained from the Department of Forensic Medicine of Ludwig 
Maximilians University, Munich, Germany; four specimens from the Netherlands 
Brain Bank; and five specimens from Institute of Neurology, London (courtesy J. 
Newcombe) and one specimen from UK MS tissue bank, London. Of the control 
specimens three were obtained from the Department of Forensic medicine of Ludwig 
Maximilians University, Munich, Germany; and one from the Institute of Neurology, 
London (courtesy J. Newcombe). In addition to these frozen blocks, 19 formalin fixed 
paraffin embedded (FFPE) and 8 additional frozen blocks were used for 
immunohistochemistry. 
Tissue blocks containing grossly visible lesions were dissected from 
anatomically distinct areas and were snap frozen in isopentane cooled in liquid 
nitrogen and later stored at -80oC. The study was approved by the ethical committee 
of the Medical Faculty of Ludwig Maximilians University, Munich, Germany. 
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Table 4.1. Tissue samples of patients and controls. 
 
Y: years; Mo: months; SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive 
multiple sclerosis.  
00-327 2 inactive 50 F 17Y SPMS
00-43 1 active 52 F 11 Y SPMS
01-018 1 inactive 48 F 8Y SPMS
01-090 1 inactive 65 M 25 Y SPMS
01-130 4 active 53 F 16 Y SPMS
1191-05 1 inactive 77 F 50 Y RRMS
1854-05 4 active and 
inactive
42 M 6 Y PPMS
403-06 1 inactive 49 F 28 mild relapsing
121 2 active 27 M 9 Y SPMS
01-135 1 active 43 M 15 Y SPMS
06-054 1 active 66 M 40 Y chronic 
progressive
03-074 1 inactive 59 M 32 Y SPMS
06-041 1 inactive 63 M 25 Y PPMS
02-046 1 inactive 71 F 23 Y chronic 
progressive
1MK2 1 active 59 F 20 Y SPMS
1MK4&5 2 active 47 F 20 Y SPMS
1MK6 1 active 29 F 8 Y SPMS
1MK7 2 active 65 M 25 Y SPMS
1 2 active 45 F 0.2 Mo acute MS
2 2 active 51 F 5 Mo acute MS
3 1 progressive 55 F 5 Y PPMS
4 1 progressive 46 F 37 Y PPMS
5 1 progressive 71 F 22 Y PPMS
6 1 inactive 64 F 28 Y SPMS
7 1 inactive 50 F 17 Y SPMS
8 1 47 M
1MK1 1 47 F
1345-06 1 48 M
696-01 3 46 F
976-06 1 49 M
1152 2 59 M control
lesion type
control
control
control
control
control
 MS 
classification
patients and 
control blocks age (Y) sex
disease 
duration 
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4.2 Methods 
4.2.1 Morphology 
a) Basic stainings: LFB-PAS, H&E, ORO 
For histochemical analysis of the frozen tissue: 10-30 µm serial sections were 
mounted on to the super frost glass slides. The extent of demyelination and 
inflammation was evaluated by the following stainings: LFB – PAS (Luxol Fast Blue-
Periodic Acid Schiff’s): 30 µm tissue sections were used for stainings, sections were 
stained first with LFB and then with PAS. LFB stains the lipoproteins in the myelin 
blue, hence the myelinated area stained blue and the demyelinated area is unstained. 
PAS stains the glycolipids pink; it is mainly used to identify macrophages which have 
phagocytised degraded myelin products. H&E (Hematoxylin & Eosin): 10 µm tissue 
sections were used for stainings. Hematoxylin stains the nucleus blue and eosin stains 
the cytoplasm pink. This staining helps in the identification of the inflamed tissue. 
ORO (Oil Red O): 10 µm tissue sections were used for stainings. ORO stains neutral 
lipids red, the staining is used to stain the macrophages which have phagocytised 
degraded myelin products. 
b) Immunohistochemistry  
Immunohistochemistry of brain sections: immunohistochemistry was 
performed on both frozen (10 µm) and paraffin (4 µm) sections using Mouse PAP or 
Rabbit PAP system (DAKO, Hamburg, Germany). Cryosections were fixed with 4% 
PFA and endogenous peroxidase activity blocked using 1.5% methanolic hydrogen 
peroxide. In case of paraffin sections, the sections were first deparaffinised twice for 
10 min in xylol, 5 min in 100% ethanol, 5 min in 90% ethanol, 5 min in 70% ethanol 
and antigen retrieval was performed by boiling the slides for 20 min in fresh citrate 
buffer pH 6.0 and then cooling down to RT. The slides were then washed once in 
distilled water and thrice in PBS followed by blocking endogenous peroxidase 
activity with 1.5% methanolic hydrogen peroxide. Later the sections were blocked 
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with 10% serum (serum of the species of secondary antibody).  Primary antibodies 
used were specific for: CD68 (mAb, DAKO), collagen I (mAb, Abcam, Cambridge, 
UK), collagen III (mAb, Abcam), collagen V (pAb, AbD SeroTec, Düsseldorf, 
Germany), biglycan (rabbit serum, a kind gift from Prof. Larry Fisher, NIH, US), 
decorin (mAb, R&D, Wiesbaden-Nordenstadt, Germany and rabbit serum, a kind gift 
from Prof. Larry Fisher), FGF9 (pAb, R&D), FGFR3 (mAb and pAb, Santa Cruz, 
Heidelberg, Germany), FGFR2 (pAb, Santa Cruz). Sections were incubated O/N at 
4oC followed by secondary: polyclonal rabbit anti-mouse (DAKO) or polyclonal 
swine anti-rabbit Ig (DAKO), for 1hr at RT and tertiary: mouse PAP (mAb, DAKO) 
or rabbit PAP (pAb, DAKO), for 30 min at RT. Bound antibodies were detected with 
diaminobenzidine (DAB) and sections were counter stained with hematoxylin. For 
immunofluorescence, primary antibodies: CD31 (mAb, R&D), collagen V (pAb, 
AbD SeroTec), GFAP-alexa 488 (mAb, Molecular Probes, Karlsruhe, Germany), and 
secondary: donkey anti-mouse alexa 488, donkey anti- sheep alexa 488 and donkey 
anti-rabbit alexa 594 (all from Molecular Probes) were used. Confocal images were 
taken from Leica SP2UV microscope. Negative controls included omission of 
primary antibody. 
Immunocytochemistry of cultured cells: Cells were fixed with 4% PFA for 
15 min at RT, washed in PBS, permeablised in 0.5% Triton X-100 and 0.5% porcine 
gelatine for 20 min at RT. Primary antibodies used are: SMI-31 (mAb, Abcam) and 
MOG (monoclonal, Z2 hybridoma). Cultures were incubated O/N at 4oC with 
primary antibody diluted in blocking buffer, followed by appropriate secondary 
antibody for 45 min at RT. The cultures were then washed with PBS followed by 
distilled water and mounted with Vectashied (Vector laboratories). 
c) Lesion classification 
Tissue blocks were classified according to defined criteria: Active demyelinated 
lesions contained abundant macrophages with myelin degradation products (LFB or 
ORO positive) either throughout the lesion (early active) or as a broad rim around the 
lesion edge (chronic active). Progressive lesions revealed mild to moderate microglia 
activation at the lesion margins without any macrophages. Chronic inactive 
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demyelinated lesions were sharply demarcated from the normal appearing white 
matter (NAWM) and without a rim of microglial activation and without any LFB or 
ORO positive macrophages.  
d) Lesion dissection 
7 demyelinated chronic inactive and 4 demyelinated active lesions were macro 
dissected manually. 4 additional active lesions were included, which were not macro 
dissected, i.e., whole tissue block with lesion and NAWM was used. To this end, 
cryosections (20 µM) from the tissue samples were mounted on PEN slides 
(P.A.L.M. Microlaser, Bernried, Germany). Every 6th section (30 µM) was stained 
with LFB to identify the demyelinated areas; the unstained sections were 
superimposed on stained LFB section and lesion area marked and then manually 
macro dissected. The macro dissected sections were then stained with LFB to counter 
check the dissected area. Control tissue samples used for qPCR (quantitative PCR) 
exclusively contained white matter. 
4.2.2 Molecular biology 
a) RNA extraction and cDNA synthesis 
Tissue was lysed in 1 ml Trizol (TRI® Reagent, SIGMA, Munich, Germany) 
and 0.1 volume of chloroform was added to the lysate and shaken vigorously. Lysate 
was incubated for 15 min on ice and later centrifuged at 4oC for 15 min at 14,000 
rpm. The aqueous phase was separated and mixed with equal volume of isopropanol 
and centrifuged at 4oC for 15 min at 14,000 rpm. The pellet was dissolved in 600 µl 
of Trizol and 0.1 volume of chloroform. The above mentioned steps were repeated till 
we got the pellet again. Pellet was washed once with 75% RNase free ethanol and 
then dissolved in 25-30 µl of RNase free water (Invitrogen, Karlsruhe, Germany). 
cDNA was synthesized using high capacity cDNA reverse transcription kit (Applied 
Biosystems (ABI), Darmstadt, Germany). 1 µg of total RNA was taken for cDNA 
synthesis with random hexamers and the procedure was followed as mentioned in the 
data sheet. 
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b) qPCR 
Gene specific primers and probes labelled with FAM-MGB or FAM-TAMRA 
or VIC-TAMRA available from ABI were used. Each reaction had 10-25 ng of RNA 
converted into cDNA, 1X primer-probe and 1X reaction buffer (Eurogentec, Köln, 
Germany) in a reaction volume of 25 µl, and was run in duplicates on an ABI 7900 
machine (Applied Biosystems). GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase) and PPIA (cyclophilin A) were used as internal controls. Primary 
data was analysed on SDS 2.3 software or RQ manager (ABI). 
Primers used were for COL1A1, COL3A1, COL5A1, COL4A1, COL4A2, 
COL4A3, COL4A4, COL4A5, COL4A6, BGN, DCN, CCL2, CXCL9, CXCL10, 
CXCL11, FGF9, GAPDH, and PPIA genes. 
c) Low Density Array (LDA) 
qPCR of dissected MS lesions was performed for 528 genes using custom 
made Low Density Arrays (LDA) (ABI). In the thesis only the genes belonging to 
ECM components, ECM modifying enzymes and factors required for oligodendrocyte 
survival, proliferation and/or differentiation are mentioned (Table 5.1, 5.2, 5.4a and 
4b). These LDAs enable us to perform several qPCR reactions simultaneously. Each 
reaction had 1-8 ng of RNA converted in to cDNA. The qPCR are run for 40 cycles. 
Data analysis was done using RQ Manager 1.2 software (ABI), taking GAPDH, 
βactin and PPIA as internal controls. 
The genes for monocyte LDA expression analysis included CD80, PDL1-B7-
H1, PDL2, CD69, CD200R, SIRPα, CD206, ADORA2A, IL-1R2, SLAM, IL-1, IL-6, 
IL-10, TNF, TGFβ, IL-12p40, CXCL10, CCL18, MPO, MMP9, CCR2, CX3CR1, 
CD62L, CD204, MT-2A, BDNF, NGF, NT-3, NT-4, NRTN, LIF, IGF-1, IL-4, IL-5, 
IFNγ, CD36, CD163, MFGE8, MERTK, CXCL8, CXCL2, CCL2, CCL5, CCL3, 
CCL4, BAFF, GAPDH and PPIA. 
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4.2.3 Cell culture 
a) Astrocytes and fibroblasts  
Human primary astrocytes of embryonic origin [Aloisi et al. 1992] and 
primary human foreskin fibroblast (kindly provided by the Virology department of  
the University of Erlangen) were grown in RPMI with 10% FCS till they reached 
confluency before being used for the final experiments. 50000-75000 astrocytes were 
seeded in each well of a 24 well plate and grown in the presence or absence of ECM 
components (collagen I, III, V, biglycan and decorin) for two days and were 
stimulated on the third day for 24 hrs with 10 ng/ml TNFα (R&D) and 100 U/ml 
IFNγ (R&D). The ECM components were coated on culture dish. In addition, a 
similar number of astrocytes and fibroblasts were grown in the absence of ECM 
components for two days. The supernatant was collected and stored at -80oC and the 
cells were lysed with TRIZOL for RNA extraction. 
b) In vitro myelination 
Neurosphere derived astrocyte monolayers: Neurospheres were prepared 
using methods modified form [Zhang et al. 1998; Reynolds et al. 1996]. 
Neurospheres were differentiated into astrocytes as described in [Reynolds et al. 
1996]. Briefly, decapitated Sprague Dawley rat pups and dissected corpus striata from 
the forebrain. Transferred the tissue into neurosphere medium consisting of 
DMDM/F12 (1:1, DMEM containing 4,500 mg/l glucose), and supplemented with 
0.105% NaHCO3, 2 mM glutamine, 5,000 U/ml penicillin, 5 µg/ml streptomycin, 5 
mM HEPES, 10-4% BSA (bovine serum albumin) (all from Invitrogen), 25 µg/ml 
insulin, 100 µg/ml apotransferrin, 60 µM putrescine, 20 nM progesterone, and 30 nM 
sodium selenite (all from Sigma), and mechanically dissociated with a Pasteur 
pipette. The suspension was centrifuged at 4°C for 5 min at 800 rpm. The cell pellet 
was resuspended in neurosphere medium and plated into an uncoated T75 tissue 
culture flask. The neurosphere medium was further supplemented with 20 ng/ml 
mouse submaxillary gland epidermal growth factor (R&D systems). The cultures 
were incubated at 37°C in a humidified atmosphere of 7% CO2 and 93% air and two 
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thirds of the media was changed every 2–3 days. After 7–10 days in vitro, the spheres 
were triturated using a Pasteur pipette to produce smaller spheres/cell clusters. 
Spheres were differentiated into astrocytes 1–2 days after trituration by plating 
spheres onto Poly-L-lysine coated coverslips in low glucose DMEM supplemented 
with 10% FBS and 2 mM L-glutamine (DMEM-FBS). After 7–10 days in culture, a 
confluent layer of astrocytes formed and dissociated embryonic spinal cord cells were 
plated onto these as described below. 
 
Myelinating Spinal Cord Cultures: Myelinating spinal cord cultures were 
prepared according to the method described previously by [Reynolds et al. 1996b; 
Sorensen et al. 2007]. Sprague Dawley (SD) rats were time-mated, with the day of 
plugging denoted as embryonic day 0.5 (E0.5), and embryos were collected on day 
E15.5. The cranial 5 to 6 mm sections of the spinal cord were dissected, stripped of 
meninges, minced with a scalpel blade, and placed in a dish containing 1 ml of 
Hank’s balanced salt solution (HBSS) without Ca++ and Mg++ (Invitrogen). The tissue 
was enzymatically dissociated by the addition of 2.5% trypsin (100 µl) (Invitrogen) 
and 1.33% collagenase (100 µl) (MP Biomedicals) for 15 min at 37°C. Enzymatic 
activity was stopped by adding 2 ml of SD solution containing 0.52 mg/ml soybean 
trypsin inhibitor, 3.0 mg/ml bovine serum albumin, and 0.04 mg/mL DNase I (all 
from Sigma) to prevent cell clumping. The cells were triturated through a glass 
pipette and spun for 5 min at 800 rpm (136 RCF). The cell pellet was resuspended in 
5 ml plating medium (PM) [Thomson et al. 2006] containing 50% Dulbecco’s 
modified Eagle’s medium (DMEM), 25% horse serum, 25% Hanks balanced salt 
solution with Ca++ and Mg++, and 2 mM L-glutamine (Invitrogen). Two coverslips 
supporting a monolayer of neurosphere derived astrocytes or Poly-L-lysine only (13 
µg/ml) (Sigma) were placed in a 35 mm Petri dish, and the dissociated spinal cord 
cells were plated onto each coverslip at a density of 150,000 cells/100 µl. The cells 
were left to attach for 2 hrs in the incubator after which 300 µl of PM and 500 µl of 
differentiation medium [Thomson et al. 2006] which contained DMEM (4,500 
mg/mL glucose), 10 ng/ml biotin, 0.5% hormone mixture (1 mg/ml apotransferrin, 20 
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mM putrescine, 4 µM progesterone, and 6 µM selenium (formulation based on N2 
mix [Bottenstein et al. 1979]), 50 nM hydrocortisone, and 0.5 mg/ml insulin (all from 
Sigma) was added. The cultures were fed thrice a week with differentiation media by 
removing half of the media and replacing it with fresh media. After 12 days in 
culture, insulin was omitted from the differentiation media. The cultures were 
maintained for 24–30 days in a humidified atmosphere of 7% CO2 and 93% air at 
37°C. In our in vitro myelinating culture system, myelination starts on day 20 and 
concludes 8-10 days later. Effect of FGF9 (human FGF9, R&D) on the in vitro 
myelinating culture was tested by applying FGF9 on day 18 (i.e. before the start of 
myelination) for 8 days. Fresh FGF9 was substituted during media change, half the 
media volume was replaced thrice a week with fresh media. Three different 
concentrations of FGF9 were tested in our experiments: 100 ng/ml, 50 ng/ml, 5 
ng/ml. After additional 8 days of culture, the cultures were fixed with 4% PFA and 
stained for axonal marker SMI-31 and myelination marker MOG and the degree of 
myelination analysed. 
c) Immune cells  
Peripheral blood mononuclear cells (PBMCs): were isolated from the blood 
of healthy donors by density gradient centrifugation. Human blood diluted with PBS 
in 1:2 ratios was over laid on 15 ml PANCOL (PAN biotech) and centrifuged for 20 
min at 1400 rpm without any break at RT. The cells at interface were collected and 
washed twice with ice cold PBS for 10 min at 2000 rpm at 4oC. The pellet consists of 
purified human PBMCs which was either used directly for experiments or was used 
for monocyte isolation. 
 
Monocytes: monocytes were isolated from PBMCs by positive selection 
(CD14 MicroBeads, Miltenyi Biotech). These monocytes were plated at a density of 
250,000 cells per well of 24 well plate and were grown in presence or absence of 
ECM components (collagen I, III and V, biglycan and decorin) for 1 day. The ECM 
components were coated on the wells of 24 well plated (see below). On the following 
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day cell supernatant was collected and the cells lysed with TRIZOL for subsequent 
RNA extraction.   
 
Macrophages: positively isolated monocytes were allowed to differentiate 
into macrophages for 9-10 days in presence of 20 ng/ml M-CSF (R&D). These 
macrophages were plated at a density of 250,00 cells per well of 24 welled plate and 
were grown in presence or absence of ECM components (collagen I, III and V, 
biglycan and decorin) for 1 day. The ECM components were coated on the wells of 
24 well plated (see below).  On the following day cell supernatant was collected and 
the cell lysed with TRIZOL for subsequent RNA extraction.  
 
T cells: 20,000  MBP specific CD4+ T cell clone ES-BP8 [Meinl et al. 1995] 
in a volume of 100 µl  and 200,000 irradiated antigen presenting cells in a volume of 
100 µl  were mixed and stimulated with  20 µg/ml human MBP (Biogenesis, Berlin, 
Germany) or 10 µg/ml  MBP 29-48 peptide (human). These cells were grown in wells 
of 96 well plate coated with indicated ECM components or in uncoated wells. 
 
Coating of the tissue culture plates with ECM proteins. 
Tissue culture dishes were coated with: Collagen I, 2 µg/cm2 (BD 
Biosciences, Heidelberg, Germany), collagen III, 2 µg/cm2 (BD Biosciences), 
collagen V, 2 µg/cm2 (BD Biosciences), biglycan, 10 µg/ml (R&D), decorin, 10 
µg/ml (R&D Systems). All the ECM proteins were diluted to the final concentration 
with Ca++, Mg++ free PBS (Invitrogen) and the cell culture dishes were incubated at 
RT for 2 hrs, and then washed with distilled water (Invitrogen) and air dried. The 
ECM proteins were tested negative for LPS contamination (Biowhittaker™ LAL kit, 
Walkersville, US). 
4.2.4 Proliferation assay 
The proliferation assay was performed in 96 well flat bottom plates in 
triplicates. MBP specific T cells (in presence of antigen presenting cell) were grown 
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in presence of 20 µg/ml human MBP or 10 µg/ml MOG 29-48 peptide in a final 
volume of 200 μl cell culture medium. After 2 days incubation, cultures were pulsed 
with 3H-thymidine (specific activity: 2 Ci/mmol; 1 μCi/well) (GE Healthcare, 
Freiburg, Germany). Samples were harvested after 24 hrs incubation, and the 
radioactivity was measured by the beta counter (MatrixTM 9600, Packard). 
4.2.5 ELISA 
Supernatants form monocytes were used for this experiment. 96-well flat 
bottomed Maxisorb plates (Nunc, Langenselbold, Germany) were coated with 100 µl 
of 1-4 µg/ml of capture antibody (mouse anti human) O/N. Wells were washed thrice 
with wash buffer and blocked with 300 µl of reagent diluent for 1 hr. After washing 
the wells, incubated 100 µl of samples or standard diluted in reagent diluent for 2 hrs. 
Cytokine standards were serially diluted starting from 1000/2000 pg/ml to make a 
seven point standard curve. Again wells were washed and incubated 100 µl of 50-300 
ng/ml of detection antibody (biotinylated goat anti human) for 2 hrs. After extensive 
washing 100 µl of streptavidin-HRP (1:200) was added and incubated for 20 min. 
The wells were washed and added 100 µl of substrate solution (tetramethyl benzidine 
activated with hydrogen peroxide). The reaction was stopped with 50 µl of  
2N H2SO4, and the optical density was measured at 405/450 nm in ELISA reader 
(Victor2™ 1420 mutilabel counter; Perkin Elmer life sciences). All the antibodies 
and streptavidin-HRP were supplied with the ELISA kit. 
4.2.6 Imaging and quantitative analysis 
Zeiss Axioplan 2 fluorescent microscope and ISIS software (metasystems) 
were used for capturing images for myelin analysis. For quantitative analysis of 
axonal density and myelination, ten images (X10 magnification) from each coverslip 
were captured. Each experiment was performed in triplicate; therefore, 30 images per 
treatment per experiment were obtained to quantify axonal density and myelination.  
Axonal density was analysed using Image J software (NIH systems, version 
1.40g). Using this software, values were obtained for the area of SMI-31 
immunoreactivity and the total field of the image. On the basis of the area of SMI-31+ 
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structures approximate axon density was calculated. To calculate the percentage of 
myelinated axons immunoreactivity of MOG+ myelin sheath was also measured using 
image J. Percentage of myelinated axons was obtained by dividing the MOG+ area by 
area obtained for axonal density. 
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5 Results 
5.1 Extracellular matrix  
5.1.1 Altered expression of ECM components in MS lesions. 
We wanted to quantify ECM molecules and ECM modifying enzymes in MS 
lesions. To this end, LDA was used for determining the gene expression profile of 
three groups namely, active demyelinated, chronic inactive demyelinated MS lesions 
and control brain white matter. 528 genes were analysed in a total of 15 MS lesions. 
In the first part of the thesis I focus on ECM components and ECM modifying 
enzymes. The up-regulated ECM components localized largely in the perivascular 
space in association with infiltrating immune cells and not in the parenchyma. This 
indicates that these ECM components might not directly affect the differentiation of 
oligodendrocytes, but rather modulate the immune response in the CNS. Hence, only 
demyelinated inactive and demyelinated active lesions are described in the results 
part.  
The expression of each gene was related to GAPDH. Each gene was 
calculated for each lesion type (Table 5.1). The table gives the absolute and relative 
values. Of the tested 50 ECM genes, 21 (42%) were up-regulated more than two-fold 
in chronic inactive lesions  and 22 (44%) in active demyelinated lesions. 15 ECM 
components COL1A1, COL3A1, COL5A1, COL5A2, COL4A1, LAMA5, LAMB1, 
LAMB2, LAMC1, BGN, FMOD, HAPLN3, HSPG2, THBS1 and THBS3 were induced 
in both chronic inactive and active lesions. 23 (46%) genes in chronic inactive lesions 
and 25 (50%) in active lesions remained unchanged, i.e. they have a fold change 
between 0.51-1.99. These up-regulated ECM components belonged to fibrillar 
collagens, basement membrane collagen, laminins, SLRPs, hyaluronan link proteins, 
perlecan and thrombospondins. 
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Table 5.1. Expression level and fold change values of 50 ECM genes  
 
Genes CB De.in De.act De.in:CB De.act:CB
Fibrillar Collagens (COL)
COL1A1 0.08 0.87 0.45 10.86 5.63
COL1A2 0.34 0.40 0.74 1.18 2.18
COL3A1 0.06 0.72 0.32 12.00 5.33
COL5A1 0.06 1.57 0.15 26.17 2.50
COL5A2 0.05 0.10 0.15 2.00 3.00
COL5A3 0.44 0.79 0.68 1.80 1.55
Basement membrane collagens (COL)
COL4A1 0.70 2.03 1.90 2.90 2.71
COL4A2 0.12 0.16 0.28 1.33 2.33
COL4A3 0.20 0.06 0.13 0.30 0.65
COL4A4 0.10 -nd- 0.11 * 1.10
COL4A5 0.65 1.07 0.84 1.65 1.30
COL4A6 0.15 0.12 0.20 0.80 1.33
Anchoring collagen (COL)
COL7A1 0.51 0.60 0.71 1.18 1.39
Nidogens (NID)
NID1 0.60 1.11 1.32 1.86 2.20
NID2 0.40 0.31 0.60 0.76 1.50
Laminins (LAMA)
LAMA1 0.68 2.09 0.36 3.07 0.53
LAMA2 0.64 1.30 0.57 2.03 0.89
LAMA3 0.18 0.22 0.36 1.22 2.00
LAMA4 0.71 1.25 1.24 1.76 1.75
LAMA5 0.13 0.99 0.93 7.62 7.15
LAMB1 0.11 1.06 0.40 9.64 3.64
LAMB2 2.58 5.83 7.89 2.26 3.06
LAMB3 0.14 0.11 0.13 0.79 0.93
LAMC1 0.34 0.83 0.79 2.44 2.32
LAMC2 -nd- -nd- -nd- * *
Lecticans
AGC1  (Aggrecan) 0.05 0.03 0.41 0.60 8.20
BCAN  (Brevican) 8.00 7.22 8.61 0.90 1.08
CSPG3  (Neurocan) 13.89 7.40 8.80 0.53 0.63
CSPG2  (Versican) 0.01 -nd- 0.01 * 1.00
absolute expression  in  % GAPDH fold change
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Table 5.1. continued 
 
CB: control brain, De.in: demyelinated inactive lesion, De.act: demyelinated active lesion, De.in:CB- 
demyelinated inactive vs control brain, De.act:CB- demyelinated active vs control brain. nd: not 
detectable due to low expression level. In total 6 control white matter from 4 subjects, 7 demyelinated 
inactive lesions from 5 subjects and 8 demyelinated active lesions from 7 subjects were used for qPCR  
analysis. * Calculation not possible because the values are under detection limit. The values below 
0.01% GAPDH are not reliable.  
Genes CB De.in De.act De.in:CB De.act:CB
Small leucine rich proteoglycans (SLRPs)
BGN  (Biglycan) 4.83 11.17 11.41 2.31 2.36
DCN  (Decorin) 2.99 6.27 5.41 2.10 1.81
FMOD  (Fibromodulin) 0.03 0.07 0.09 2.33 3.00
LUM  (Lumican) 0.09 0.15 0.24 1.67 2.67
Hyaluronan and proteoglycan link proteins (HAPLNs)
HAPLN1 0.09 -nd- 0.02 * 0.22
HAPLN2 29.85 5.08 25.74 0.17 0.86
HAPLN3 0.05 0.29 0.36 5.80 7.20
HAPLN4 0.03 0.17 0.03 5.67 1.00
Heparan sulphate proteoglycan (HSPG)
HSPG2  (Perlecan) 0.63 2.75 1.51 4.37 2.40
Tenascins (TNs)
TNC 3.68 9.46 3.49 2.57 0.95
TNR 5.05 2.78 3.98 0.55 0.79
Thrombospondins (THBSs)
THBS1 0.12 0.98 0.41 8.17 3.42
THBS2 2.75 4.22 4.05 1.53 1.47
THBS3 0.01 0.02 0.03 2.00 3.00
THBS4 0.83 1.08 1.09 1.30 1.31
Fibrillins (FBNs)
FBN1 2.59 3.12 1.46 1.20 0.56
FBN2 0.04 0.03 0.09 0.75 2.25
FBN3 0.11 0.10 0.13 0.91 1.18
Others
FN1  (Fibronectin) 2.60 4.86 3.94 1.87 1.52
RELN  (Reelin) 0.08 0.63 0.04 7.86 0.50
VTN  (Vitronectin) 0.03 0.03 0.03 1.00 1.00
absolute expression  in  % GAPDH fold change
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5.1.2 Fibrillar collagens and small leucine rich proteoglycans form 
perivascular fibrosis in MS lesions 
 
  Our expression profiling identified a total of 22 components up-regulated in 
active MS lesions and 21 in chronic inactive MS lesions. When considering the 
relative induction in MS lesions, the absolute expression level and possible 
interactions with each other, our interest was directed to the fibrillar collagens and the 
SLRPs.  
We noted a strong induction of COL1A1, COL3A1, COL5A1 and COL5A2 
chains, both in active and chronic inactive demyelinated lesions (Table 5.1). These 
collagen chains interact to form collagen type I, III and V, which are grouped as 
fibrillar collagens known to act as structural proteins. The different chains of collagen 
I and V interact to form homotrimeric or heterotrimeric collagens, whereas collagen 
III chain forms only homotrimeric collagen. Two SLRPs biglycan and decorin were 
also strongly induced in active and inactive demyelinated lesions (Table 5.1). Decorin 
and biglycan can interact (decorate) with fibrillar collagens and participate in fibril 
formation, but decorin alone can inhibit fibril formation in vitro. To further confirm 
the induction of these ECM components and to determine their localization we 
performed immunohistochemistry on chronic inactive, active demyelinated lesions 
and control brain.  
 
 
 
Fig. 5.1 Overview of the extent of induction of fibrillar collagens in MS lesions.  Immunostaining 
for collagen V is shown in A-C. Specific antibody binding was visualized with DAB as a substrate 
resulting in a brown colour. Nuclei were counterstained blue with hematoxylin. Collagen V is 
deposited around small and big blood vessels in a chronic inactive MS lesion. The strong expression of 
collagen V in the lesion core decreases to the lesion edge and in the normal appearing white matter 
(NAWM) it becomes similar to that of control brain.  
Results  37 
 
To determine the localization of fibrillar collagens, biglycan, and decorin in 
MS lesions, immunostaining was performed with a total of 6 different primary 
antibodies. We noted that antibodies to three fibrillar collagens, decorin and biglycan 
gave a similar staining pattern. In the control brain we saw faint staining around 
blood vessels, which is similar to the staining observed in the NAWM (Figure 5.1C). 
In contrast, in both active and chronic inactive MS lesions an intense staining of 
fibrillar collagens, decorin, and biglycan was seen (Figures 5.2A-D, J, K), which was 
localized around small, medium and large blood vessels (Figure 5.1A). In the larger 
blood vessels with an extended perivascular (Virchow Robin) space (space between 
the endothelial basement membrane and the astrocytic glia limitans) a mesh of 
fibrillar collagen, biglycan and decorin could be seen (Figure 5.2). In chronic active 
and also early active lesions the infiltrating immune cells in the perivascular space 
were in close contact with fibrillar collagens, biglycan and decorin (Figure 5.2). 
Staining for collagens I, III, and V showed that the up-regulated fibrillar collagens 
were seen in the perivascular space also in early active MS lesions (Figure 5.2G). The 
up-regulation of ECM molecules seen in the lesion area decreased with the distance 
from the lesion core and became similar to the expression seen in the control brain 
(Figure 5.1A-C).  
We noted that the deposition of collagen V extended beyond the perivascular 
space; Collagen V was seen in the brain parenchyma of 6/8 early active lesions 
(Figure 5.2F-H) and was expressed most likely in astrocytes. Infiltrating immune 
cells in the parenchyma of such an active lesion could be positively stained with 
biglycan (Figure 5.2I).  
Double staining of the lesions with the endothelial cell marker 
CD31+collagen V and GFAP+collagen V revealed that the collagens are located 
between the endothelial cells and the astrocytic glial limitans (Figure 5.3). 
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Fig. 5.2 Localization of ECM components up-regulated in MS lesions. Sections of active lesions    
(A-C, F-I), chronic inactive lesions (D, J-K) and control white matter (E, L) were immunostained for 
indicated antibody. Specific antibody binding was visualized with DAB as a substrate resulting in a 
brown colour. Nuclei were counterstained blue with hematoxylin. Collagen I(A), collagen III (B,D) 
and collagen V (C) form a mesh in the perivascular space in MS lesions. In the control brain fibrillar 
collagens can be detected around blood vessels at lower level (collagen I in E). (F-H) In active lesions 
collagen V was found around blood vessels (arrow in F) and also outside of the perivascular space 
(arrowhead in F and H).  Biglycan is detected in infiltrating immune cells in active lesions (I) and in 
chronic inactive lesions the fibrotic mesh in the perivascular space also contains biglycan (J) and 
decorin (K). In the control brain biglycan (L) and decorin (not shown) are seen around blood vessels at 
a lower level (L). PVS = perivascular space 
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Fig. 5.3  Fibrillar collagens in the perivascular space. Immunofluorescence of inactive lesion  
A) GFAP (green) and collagen V (red)  B) CD31 (green) and collagen V (red) .Fibrillar collagens form 
a mesh in the perivascular space of the blood vessel. The mesh formed by fibrillar collagens is strictly 
limited to the perivascular space between endothelial cells (CD31 positive) and the astrocytic scar 
(GFAP positive) in the parenchyma.  
 
5.1.3 ECM modifying enzymes in control brain and MS lesions  
The ECM modifying enzymes were also tested, because the absolute levels or 
the turnover of the ECM components depend upon the expression of these enzymes. 
In this regard 34 enzymes were analysed. In the control white matter, out of 26 matrix 
metalloproteinases (MMPs), 7 MMPs, namely MMP2, MMP14-17, MMP24, and 
MMP28 were clearly expressed (>0.1% GAPDH). In chronic inactive lesions 10 
(29%) and in active lesions 7 (21%) of all the analysed ECM modifying enzymes 
were up-regulated at least two-fold (Table 5.2). Five of them, namely MMP9, 
MMP11, MMP14, MMP19 and tissue inhibitor of matrix metalloproteinase (TIMP) 1 
were induced in both chronic inactive and active lesions. We also noted that other 
ECM modulating enzymes were differentially regulated. MMP2, MMP9 and MMP19 
were stronger induced in active lesions; MMP17, MMP24, and MMP28 were 
stronger up regulated in chronic inactive lesions. Of the four TIMPs analysed, TIMP1 
was the one being most strongly regulated, it was induced by about 6-7 fold in both 
active and chronic inactive lesions. While TIMP3 was up-regulated in chronic 
inactive lesions and only slightly in active lesions. Expression of other two TIMPs, 
TIMP2and -4 was similar to that of the control brain (Table 5.2). The expression of 9 
(26%) and 14 (41%) genes from chronic inactive and active demyelinated lesions 
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respectively remained unchanged, i.e., they have a fold change between 0.51-1.99. 
We also tested the expression of three out of 4 collagenases (degrading fibrillar 
collagen), namely MMP1, -8 and -13. All the three collagenases were not detected in 
our study, either their expression was lower than the detection limit or else they were 
not expressed in the lesions.  
 
Table 5.2. Expression level and fold change values of 34 ECM modifying enzymes. 
 
Genes CB De.in De.act De.in:CB De.act:CB
A disintegrin and metalloproteinase domains (ADAMs)
ADAM8 0.11 0.05 0.31 0.45 2.82
ADAM10 16.40 13.58 13.23 0.83 0.81
ADAM12 0.30 0.29 0.40 0.97 1.33
ADAM17 1.29 0.85 1.32 0.66 1.02
A disintegrin like and metalloproteinase with thrombospondin type 1 motifs (ADAMTs)
ADAMTS1 7.38 7.88 3.92 1.07 0.53
ADAMTS4 16.04 3.24 15.15 0.20 0.94
ADAMTS5 0.04 0.17 0.06 4.25 1.50
Matrix metalloproteinases (MMPs)
MMP1 -nd- -nd- -nd- * *
MMP2 0.61 1.09 3.36 1.79 5.50
MMP3 -nd- -nd- -nd- * *
MMP7 -nd- -nd- 0.03 * *
MMP8 -nd- -nd- -nd- * *
MMP9 0.01 0.05 0.13 5.00 13.00
MMP10 -nd- -nd- -nd- * *
MMP11 0.05 0.30 0.30 6.00 6.00
MMP12 -nd- -nd- -nd- * *
MMP13 -nd- -nd- -nd- * *
MMP14 1.00 5.71 4.61 5.71 4.61
MMP15 0.71 0.83 0.36 1.17 0.51
MMP16 0.75 0.97 1.03 1.29 1.37
MMP17 0.39 5.05 0.36 12.95 0.92
MMP19 0.01 0.04 0.08 4.00 8.00
MMP20 -nd- -nd- -nd- * *
MMP21 0.07 -nd- 0.07 * 1.00
MMP23 0.02 0.01 0.01 0.50 0.50
MMP24 0.37 1.21 0.34 3.27 0.92
MMP25 -nd- -nd- 0.01 * *
MMP26 -nd- -nd- -nd- * *
MMP27 -nd- -nd- -nd- * *
MMP28 0.24 0.75 0.08 3.13 0.33
absolute expression  in  % GAPDH fold change
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Table 5.2. Continued 
 
 
 
CB: control brain, De.in: demyelinated inactive lesion, De.act: demyelinated active lesion, De.in:CB- 
demyelinated inactive vs control brain, De.act:CB- demyelinated active vs control brain. nd: not 
detectable due to low expression level. In total 6 control white matter from 4 subjects, 7 demyelinated 
inactive lesions from 5 subjects and 8 demyelinated active lesions from 7 subjects were used for qPCR 
analysis. * Calculation not possible because the values are under detection limit. The values below 
0.01% GAPDH are not reliable.  
  
 
5.1.4 Fibrillar collagens up-regulated in MS lesions do not modulate T 
cell proliferation. 
As we observed a close association of infiltrating immune cells with fibrillar 
collagens, decorin, and biglycan in MS lesions, we tested the effect of these up-
regulated ECM proteins on the activation of MBP-specific CD4+ T cells. 
  To this end, MBP-specific CD4+ T cells were cultured in presence of fibrillar 
collagens (I, III, V) and stimulated with human MBP or the relevant peptide for this 
clone (MBP 29-48) and PBMC as antigen presenting cells. The antigen specific 
proliferation was not modified by the presence of either collagen I, III or V (Figure 
5.4).  
                               
 
 
 
 
 
 
 
 
Genes CB De.in De.act De.in:CB De.act:CB
Tissue inhibitor of metalloproteinases (TIMPs)
TIMP1 0.97 5.96 7.00 6.14 7.22
TIMP2 13.78 9.56 13.82 0.69 1.00
TIMP3 9.21 22.98 15.51 2.50 1.68
TIMP4 0.88 0.69 0.98 0.78 1.11
absolute expression  in  % GAPDH fold change
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Fig. 5.4  Unaltered antigen specific proliferation of lymphocytes in presence of fibrillar collagens. 
MBP specific human CD4+ T cells (ES-BP8) were grown in presence of antigen presenting cells and 
antigen (human MBP or human MBP 29-48 peptide) for 2 days and pulsed with 3H-thymidine for 
additional 24 hrs. Cells incorporated 3H-thymidine, which indicates proliferation. Proliferation was 
analysed by measuring radioactivity in a beta counter and shown as counts per minute (cpm). These 
cells were grown in dishes coated with the indicated collagen or on uncoated dishes (control).  Error 
bars indicate the standard deviation of triplicates. Shown data is a representative of two experiments. 
 
5.1.5 Fibrillar collagens up-regulated in MS lesions modulate chemokine 
production of monocytes. 
Purified monocytes and macrophages were cultured in the presence or absence 
of fibrillar collagens and SLRPs found to be up-regulated in MS lesions. 
Subsequently the expression of 46 immune related genes (mentioned in materials and 
methods) was quantified by qPCR.  
Collagen I reduced the expression level of CCL2, CCL4, IL-10 and IL-1β in 
monocytes by about 50%, whereas collagen III reduced them by 20-40%. In contrast, 
collagen V, biglycan and decorin did not modulate the production of any of the 46 
genes tested (Figure 5.5 A-D). 
0
500
1000
1500
2000
2500
3000
Co
lla
ge
n 
I +
 M
BP
Co
lla
ge
n 
III
 +
 M
BP
Co
lla
ge
n 
V 
+ 
M
BP
Co
nt
ro
l +
 M
BP
Co
nt
ro
l -
M
BP
cp
m
Results  43 
 
  
  
  
Fig. 5.5 Collagen I and III reduced the expression of monocytic chemokine-cytokine. Human 
monocytes were isolated by positive selection (CD14 MicroBeads) and cultured in dishes coated with 
the indicated ECM component for 24 hours. Monocytes grown in uncoated dishes were taken as 
control. Expression of A) CCL2, B) CCL4, C) IL-1B, D) IL-10 was determined by qPCR in relation to 
housekeeping gene GAPDH and is indicated as percentage of the control dish. Error bars indicate the 
SEM of three individual experiments. 
 
 
We went on to test whether the reduced transcript levels detected in our qPCR 
screening were mirrored at the protein level. The presence of CCL2, CCL4, IL-10 and 
IL-1β in the supernatant of monocytes was detected by ELISA in three individual 
experiments. While the amount of released CCL4, IL-10, and IL-1β was not 
significantly reduced in these experiments (Figure 5.6B), reduction of CCL2 that 
mirrored the transcript levels was noted. Collagen I reduced the production of CCL2  
protein by 60% and collagen III by 25% (Figure 5.6A). This decrease in the 
production of CCL2 by monocytes is not due to the absorption of CCL2 by the 
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collagens. In a parallel experiment 1730 pg/ml CCL2, the spontaneous level produced 
by unstimulated monocytes, was added to the medium in the collagen coated culture 
dishes and >95% of CCL2 could be recovered from the supernatant after 24 hrs. This 
indicates that the reduced amount of CCL2 in the supernatant is due to reduced 
release by monocytes and not due to an absorption by collagen.  
Macrophages grown on collagen I, III, V, biglycan and decorin did not show 
significant regulation in the expression of any of the 46 genes tested. 
 
   
Fig. 5.6 Collagen I decreased CCL2 production by monocytes. Human monocytes were isolated by 
positive selection (CD14 MicroBeads) and cultured in dishes coated with the indicated ECM 
component for 24 hours. Monocytes grown in uncoated dishes were taken as control. The release of A) 
CCL2 B) CCL4, IL-1 and IL-10 in the culture supernatant was measured by ELISA and is indicated as 
percent of amount produced in control dish without ECM component. Error bars indicates the SEM of 
three individual experiments. 
 
 
5.1.6 In vitro production of ECM proteins by astrocytes and fibroblasts 
Possible sources of the ECM molecules up-regulated in the perivascular space 
are fibroblasts and astrocytes. Therefore the in vitro production of ECM components 
by human foreskin fibroblast (HFFs) and human primary astrocytes was analysed by 
qPCR. Both HFFs and astrocytes produced fibrillar collagens, biglycan and decorin; 
albeit with varying, expression levels (Table 5.3). 
 
Results  45 
 
Table 5.3. Expression levels of ECM components produced by HFF and astrocytes in vitro. 
  
 
Human primary astrocytes and human primary foreskin fibroblasts were grown for 2 days. RNA was 
extracted with TRIZOL and expression of collagen I, III and V, biglycan and decorin quantified by 
qPCR.  * Expression values in % GAPDH. 
 
 
5.2 Factors involved in proliferation, maturation and/or survival of 
oligodendrocytes 
5.2.1 Altered expression of proliferation, maturation and/or survival 
factors for oligodendrocytes in MS lesions 
Expression profiling of remyelinated MS lesions have not been done till date. 
We were interested to screen factors which promote some lesions to undergo 
remyelination and factors which might inhibit others form undergoing remyelination. 
To address this question LDA was used for determining the gene expression profile 
of four groups namely, remyelinating/ed lesions (n=4), active lesions (n=8), chronic 
inactive demyelinated lesions that failed to remyelinate (n=7) and control brain white 
matter (n=6). The expression levels of 32 factors regulating oligodendrocyte 
development and 18 receptor genes were quantified (Table 5.4a and 5.4b) and the 
gene regulation was calculated in terms of median value of the group with respect to 
GAPDH. The analysed oligodendrocyte regulating factors belonged to following 
groups: neurotrophins (NTs), fibroblast growth factors (FGFs), neuregulins, platelet- 
derived growth factors (PDGFs), insulin like growth factors (IGFs), interleukin 6 
family (IL-6 family), transforming growth factor (TGF) and others. Of the tested 32 
factors regulating oligodendrocyte development 12 (38%) factors were up-regulated 
in remyelinated lesions, 12 (38%) in chronic inactive lesions and 13 (40%) in active 
Genes
HFF* Astrocytes*
COL1A1 816 84.4
COL1A3 949 3.4
COL1A5 0.33 2.2
BGN 2.08 2.9
DCN 18.4 0.7
Cell types
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demyelinating lesions. TGF-β, CTGF (connective tissue growth factor) and HGF 
(hepatocyte growth factor) were up-regulated in all the three lesion types. Four of the 
up-regulated genes namely NGFB, NT4/5, FGF5 and PDGFB, were up-regulated in 
only chronic inactive and active demyelinated MS lesions. None of the genes detected 
was down-regulated in any of the lesion types. 30-45% of genes in each group 
remained unchanged; they had a fold change between 0.51-1.99. Surprisingly 4 
members of IL-6 family were up-regulated in the remyelinated lesions. Five of the 
analysed genes; namely FGF1, FGF2, PDGFA, PDGFB, TGF-β, CTGF and GRN 
were abundantly expressed in all the lesion types and in the control brain. FGF1 and 
PDGFA were the most abundant genes detected with more than 20% GAPDH 
expression value. 
Of the tested 18 receptors for oligodendrocyte regulating factor, 8 (44%) 
genes were up-regulated in remyelinated and 4 (22%) in both chronic inactive and 
active demyelinated MS lesions. One (6%) gene was down-regulated in chronic 
inactive and 2 (11%) genes in active demyelinated lesions. 45-67% genes in each 
group remained unchanged. ERBB3, NTRK2, FGFR2 and IL6ST were abundantly 
expressed in all the lesion types and in the control brain, with an expression value 
greater than 10% GAPDH. These findings indicate that alteration of proliferation, 
maturation and/or survival factors for oligodendrocytes and their receptors occurs 
during the development of different stages of MS lesions.  
 
Table 5.4a. Expression value and fold change values of 32 oligodendrocyte regulating factors. 
 
Genes CB Re De.in De.act Re:CB De.in:CB De.act: CB
Neurotrophins
ARTN 0.005 -nd- -nd- 0.011 * * 2.20
BDNF 0.003 -nd- -nd- 0.004 * * 1.33
GDNF 0.017 0.034 -nd- 0.019 2.00 1.12
NGFB 0.023 -nd- 0.186 0.07 * 8.09 3.04
NRTN 0.182 -nd- -nd- -nd- * * *
NT4/5 0.005 -nd- 0.011 0.025 * 2.20 5.00
PSPN -nd- -nd- -nd- -nd- * * *
values in % GAPDH fold change
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Table 5.4a. Continued 
Genes CB Re De.in De.act Re:CB De.in:CB De.act: CB
FGFs
FGF1 40.945 76.346 26.551 35.728 1.86 0.65 0.87
FGF2 3.575 9.158 5.671 4.957 2.56 1.59 1.39
FGF5 0.0001 -nd- 0.005 0.002 * 50.00 20.00
FGF8 0.004 0.021 -nd- 0.011 5.25 * 2.75
FGF9 0.016 0.016 0.118 0.02 1.00 7.38 1.25
Neuregulins
NRG1 0.011 0.007 0.027 0.007 0.64 2.45 0.64
NRG2 0.641 1.194 5.817 1.143 1.86 9.07 1.78
NRG4 0.562 0.851 0.437 0.378 1.51 0.78 0.67
PDGFs
PDGFA 21.271 28.217 14.704 21.003 1.33 0.69 0.99
PDGFB 1.178 1.589 3.899 2.772 1.35 3.31 2.35
PDGFC 0.446 1.171 0.578 0.988 2.63 1.30 2.22
PDGFD 0.086 0.294 0.249 0.111 3.42 2.90 1.29
IL-6 family
CNTF 0.167 0.467 0.119 0.264 2.80 0.71 1.58
CLCF1 0.022 0.051 -nd- 0.208 2.32 * 9.45
CTF1 0.161 0.464 0.455 0.224 2.88 2.83 1.39
IL-6 0.035 0.072 -nd- 0.097 2.06 * 2.77
LIF -nd- 0.017 -nd- 0.146 * * *
IGFs
IGF1 0.341 0.232 0.486 0.283 0.68 1.43 0.83
IGF2 0.225 0.372 0.385 0.579 1.65 1.71 2.57
Others
CTGF 1.467 4.506 9.609 5.154 3.07 6.55 3.51
EPO -nd- -nd- -nd- -nd- * * *
FIGF 0.214 0.289 0.165 0.323 1.35 0.77 1.51
GRN 1.026 1.294 1.186 1.676 1.26 1.16 1.63
HGF 0.12 0.459 0.314 1.247 3.83 2.62 10.39
TGF 5.213 11.559 11.489 14.57 2.22 2.20 2.79
values in % GAPDH fold change
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Table 5.4b. Expression level and fold change value of 18 receptors for oligodendrocyte regulating 
factors. 
 
 
 
CB: control brain, De.in: demyelinated inactive lesion, De.act: demyelinated active lesion,  
Re: remyelinated lesion, De.in:CB- demyelinated inactive vs control brain, De.act:CB- demyelinated 
active vs control brain, Re:CB-remyelinated vs control brain, nd: not detectable due to low expression 
level. In total 6 control white matter from 4 subjects, 7 demyelinated inactive lesions from 5 subjects,  
8 demyelinated active lesions from 7 subjects and 4 remyelinated lesions from 3 subjects were used for 
qPCR analysis. * Calculation not possible because the values are under detection limit. The values 
below 0.01% GAPDH are not reliable.  
  
 
 
5.2.2 FGF9 and its receptor expression in MS lesions 
Of the 32 proliferation, maturation and/or survival factors analysed, 4 of them; 
namely FGF9 (fibroblast growth factor 9), NRG1 (neuregulin1), NRG2 and PDGFB 
were up-regulated (Table 5.4a) in chronic inactive demyelinated lesions which failed 
to remyelinate. PDGFB is a proliferation and survival factor for oligodendrocytes 
Genes CB Re De.in De.act Re:CB De.in:CB De.act: CB
EGFR 1.551 2.814 1.982 1.196 1.81 1.28 0.77
ERBB3 33.819 48.079 9.239 13.988 1.42 0.27 0.41
ERBB4 2.908 4.667 4.536 2.196 1.60 1.56 0.76
NTRK1 0.029 0.088 0.284 0.078 3.03 9.79 2.69
NTRK2 15.913 39.239 22.653 19.537 2.47 1.42 1.23
NTRK3 2.458 4.042 9.164 3.649 1.64 3.73 1.48
FGFR1 3.037 5.365 6.055 7.203 1.77 1.99 2.37
FGFR2 11.713 18.302 10.593 14.032 1.56 0.90 1.20
FGFR3 3.583 11.570 6.692 0.695 3.23 1.87 0.19
FGFR4 0.051 0.127 0.118 0.089 2.49 2.32 1.75
PDGFRA 4.777 10.874 3.620 3.104 2.28 0.76 0.65
PDGFRB 1.426 3.213 2.720 2.431 2.25 1.91 1.71
IGFR1 3.440 7.262 7.789 6.406 2.11 2.26 1.86
IGFR2 0.884 1.456 0.999 1.976 1.65 1.13 2.24
IL6ST 23.770 57.686 24.335 27.040 2.43 1.02 1.14
LIFR 0.003 -nd- -nd- 0.002 * * 0.85
CNTFR 2.918 2.646 4.538 2.529 0.91 1.55 0.87
RET 0.011 -nd- -nd- 0.023 * * 2.03
values in % GAPDH fold change
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[Dell'Albani et al. 1998; Baron et al. 2002]. Its presence in the demyelinated inactive 
lesions states that these lesions have factors promoting oligodendrocyte proliferation, 
but their effect might be masked by the presence of certain inhibitory factors in the 
lesions. NRG1 has been shown to influence peripheral nervous system myelination, 
but its role in CNS myelination is unclear [Brinkmann et al. 2008]. Hence we tried to 
understand the role of FGF9 and NRG2 in myelination/remyelination. To further 
confirm the up-regulation of FGF9 and NRG2 we analysed their expression in 6 
additional demyelinated chronic inactive lesions and 3 control white matter by qPCR. 
Surprisingly we could not reproduce NRG2 up-regulation after increasing the sample 
size for chronic inactive demyelinated lesions and control brain. Hence, we 
discontinued NRG2 for the follow up studies. In contrast, FGF9 was found to be up- 
regulated even after the increase of sample size. Closer look at individual chronic 
inactive demyelinated lesions revealed that some of the lesions had FGF9 expression 
levels similar to that of the control brain and only a subset of the lesions had higher 
expression levels (Figure 5.7). FGF9 levels in the remyelinated and active 
demyelinated lesions were similar to that of the control brain (Table 5.4a). Thereby 
suggesting that FGF9 could be a probable inhibitory factor for a subset of 
demyelinated lesions to recover from the demyelinating insult.  
The two main receptors for FGF9 are FGFR2 and FGFR3. These receptors 
were expressed in all the lesion type as examined by LDA. In the demyelinated 
chronic inactive lesions where FGF9 expression was up-regulated, the expression of 
FGFR2 is similar to control brain and FGFR3 expression was up-regulated 
approximately by 2 fold (Table 5.4b).  FGFR2 and FGFR3 can also act as a receptor 
for other FGFs.  
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Fig. 5.7 FGF9 up-regulation in a subset of demyelinated inactive lesions. The demyelinated 
inactive lesions and remyelinated lesions were macro dissected and the RNA was extracted with 
TRIZOL. FGF9 expression in 9 control white matter (from 8 subjects), 13 demyelinated inactive 
lesions (from 9 subjects) and 4 remyelinated lesions (from 3 subjects) was determined by qPCR. The 
values represented here are in relation to housekeeping gene GAPDH and were obtained from 
individual qPCR. Each data point is an individual lesion/control white matter.  
 
 
To understand which cells in the lesions could produce FGF9, we performed 
immunohistochemistry of the demyelinated chronic inactive lesions and control white 
matter with the antibody directed against FGF9. The results of the immunostaining 
were not convincing as we sometimes observed nuclear staining (data not shown). 
Similar staining pattern was observed with the FGF9 receptors (FGFR2 and FGFR3). 
These stainings were discussed with neuropathologist, Prof. Lassmann for its 
specificity and later regarded as unspecific.  
 
FGF9 is known to be produced largely by neurons [Kanda et al. 1999; Todo et 
al. 1998; Nakamura et al. 1997]. Hence, the neuronal presence in the demyelinated 
chronic inactive lesions and control white matter was analysed by qPCR for NFL 
(neurofilament protein, light polypeptide) and NFM (neurofilament protein, medium 
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polypeptide). All the three demyelinated chronic inactive lesions with higher 
expression of FGF9 showed higher expression of NFM and NFL (Figure 5.8A and 
5.8B). Thereby, stating that in these lesions neuronal contribution for FGF9 exists. 
This also confirms yet another source of FGF9 in the lesions which have moderate 
expression of FGF9 but low expression of NFL and NFM. In such lesion astrocytes, 
fibroblasts or oligodendrocytes might contribute for higher FGF9 levels. To this end 
primary human fibroblast and astrocytes were tested for their in vitro production of 
FGF9. In vitro human primary fibroblast produce higher amounts of FGF9 compared 
to human primary astrocytes, as shown by qPCR. Stimulation with TNFα, IFNγ, 
TNFα+IFNγ, IL1 or IFNβ of fibroblasts did not significantly alter the expression 
level of FGF9 (data not shown). The level of expression by astrocytes was near the 
detection limit and not clearly modulated by the applied cytokines. 
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              B 
 
Fig. 5.8 Neuronal contribution to high FGF9 levels in a subset of FGF9 high lesions. The 
demyelinated inactive lesions were macro dissected as mentioned before. A) NFL and B) NFM 
expression in 9 control white matter (from 8 subjects) and 10 demyelinated inactive lesions (from 9 
subjects) was determined by qPCR. The values represented here are in relation to housekeeping gene 
GAPDH and each data point is an individual lesion/control white matter. Lesions marked with * are 
same in figure A and B 
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5.2.3 FGF9 blocks in vitro myelination  
To address the question whether FGF9 affects myelination, an in vitro system 
of myelination was applied in collaboration with Prof. C. Linington. The below 
mentioned experiments were done in his lab.   
 
FGF9 inhibits myelination and maturation of oligodendrocytes  
  In order to deduce the effect of FGF9, the degree of myelination in the 
cultures was analysed by calculating the number of myelin positive axons (double 
positive for SMI-31 and MOG) among total number of axons (single positive for 
SMI-31). A dose dependent decrease in the myelination was observed. Myelination in 
the culture was almost completely abolished at 100 ng/ml of FGF9, compared to the 
untreated cultures (Figure 5.9A). Next we tested if this decrease in myelination was 
because of the effect on oligodendrocyte or on the axons. To this end the number of 
MOG+ (mature) oligodendrocytes in the myelinating cultures was analysed. At the 
highest concentration (100 ng/ml) of FGF9 used ~60% decrease in the number of 
MOG+ cells per field of vision was observed compared to the untreated cultures. 
FGF9 showed effect on oligodendrocytes, particularly on the maturation of 
oligodendrocytes, thereby inhibiting their myelin production (Figure 5.9B).  
 
 
No effect of FGF9 on axonal density in the cultures 
In our experiments FGF9 did not influence axonal density in the myelinating 
cultures at any of the above mentioned FGF9 concentration used. The axonal density 
which was calculated as percentage of SMI-31+ axons in a particular field remained 
unaltered through the experiment (Figure 5.9C). 
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                       C 
 
 
 
Fig. 5.9 FGF9 selectively blocks myelination in vitro. The mixed cultures from E15.5 rat were grown 
on astrocytic monolayer (derived from rat) for 12 days in presence of insulin, and after 12 days the 
insulin was omitted from the culture media to promote differentiation of oligodendrocytes. FGF9 was 
applied to the cultures on day 18 for 8 days, half of the media was changed every third day with fresh 
media supplemented with FGF9. On day 26 the cultures were fixed and immunostained and analysed 
by fluorescent microscopy. A) FGF9 inhibits in vitro myelination in a dose dependent manner. 
Myelination is almost completely inhibited at 100 ng/ml of FGF9. B)  FGF9 reduces the number of 
MOG+ cells in the myelinating culture. C) FGF9 does not alter axonal density in the myelinating 
cultures. Axonal density is calculated as the percentage of SMI-31+ area in the total field. Error bars 
indicate the SEM of three individual experiments. 
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6 Discussion 
Focal demyelination with limited remyelination is one of the hallmarks of MS. 
Why most lesions fail to remyelinate is unclear, as the CNS contains an endogenous 
repair mechanism that normally acts to ensure rapid and essentially complete 
remyelination. The aim of this thesis was to get insight into possible mechanisms 
explaining the frequent failure of remyelination in MS lesions. This failure might be 
due to alterations of the extracellular matrix and/or alterations of factors mediating 
growth, survival and differentiation of oligodendrocytes. 
Alterations of the ECM in MS lesions 
In this study, we have quantified alterations of ECM components in MS 
lesions. The most strongly altered ECM components were the chains forming fibrillar 
collagens, namely COL1A1, COL3A1, COL5A1, COL5A2, and the SLRPs biglycan 
and decorin. Decorin and biglycan can interact with and decorate fibrillar collagens 
[Danielson et al. 1997]. The up-regulation of some of these fibrillar collagen chains 
and biglycan is in parallel with previous proteomic results of demyelinated MS 
lesions (supplementary table1 in [Han et al. 2008]). Immunostaining showed that 
these fibrillar collagens and SLRPs were localized largely in the perivascular space 
associated with immune cells and not in the parenchyma. This indicates that these 
ECM components might not directly affect the differentiation of oligodendrocytes, 
but rather modulate the immune response in the CNS.   
 Collagens maintain the structure of various tissues and also have various 
other functions. The most important fibrillar collagens are type I, II, III, V, XI, XXIV 
and XXVII form collagen fibrils and provide the stiff, resilient characteristics of 
many tissues like tendon, ligament, cartilage, skin, cornea etc [Okada et al. 2007; Van 
der Rest et al. 1991]. Collagens have a characteristic triple helical conformation and 
the triple helix is formed by the homotrimeric or heterotrimeric interaction of three 
individual collagen polypeptide chains [Van der Rest et al. 1991].  
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These fibrillar collagens are the molecular components of the perivascular 
fibrosis in MS lesions as elaborated in this thesis. The presence of fibrous structures 
around blood vessels in chronic CNS inflammation had been noted by 
neuropathologists [ Speilmeyer 1922; Levine 1970].Modern imaging techniques 
which combine three MRI sequence modalities, suggest that the perivascular space 
regulates inflammation in the brain of MS patients [Wuerfel et al. 2008]. These 
perivascular deposits are rather a feature of chronicity, since such a fibrosis (based on 
BGN and DCN staining) was not mirrored in the analysed EAE lesions. This view is 
also supported by the finding in this study that the induction of fibrillar collagens is 
more prominent in chronic inactive lesions than in active lesions. Perivascular fibrosis 
is also observed in liver cirrhosis, hypertensive heart failure and atherosclerosis 
[Lopez et al. 2006], where collagens I and III form the perivascular deposits, which is 
similar to that observed in chronic MS lesions. The up-regulation of some of these 
fibrillar collagen chains and of biglycan observed by us is in harmony with previous 
proteomic study on demyelinated MS lesions (Supplementary Table 1 in [Han et al. 
2008]). 
The ratio of synthesis and degradation determines the final protein level. 
Therefore we analysed in parallel to the ECM components also the potential 
degrading enzymes. The most important collagenases which degrade fibrillar 
collagens are MMP1, MMP8 and MMP13 [Yong et al. 2001], all of which  were not 
detected in  our MS lesions.  
In addition to the MMPs above mentioned, we observed a strong induction of 
MMP2, -9, -11, -14 and -19 in both active and chronic inactive lesions. MMP2 and -9 
which were strongly induced in active lesions, are known to participate in the BBB 
leakage [Anthony et al. 1997; Cuzner et al. 1996; Maeda et al. 1996]. A possible 
involvement of MMP19 in the pathogenesis of MS by remodelling the ECM of the 
CNS has been shown recently by Van Horssen et al. In active MS lesions strong 
MMP19 immunoreactivity was observed in parenchymal and perivascular 
macrophages. In the normal brain white matter MMP19 is constitutively expressed by 
microglia throughout the brain parenchyma, thereby suggesting a physiological role 
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for MMP19 in the CNS [Van Horssen et al. 2006]. We also observed strong induction 
of MMP11, -17, -24, and -28 in the chronic inactive lesions, the involvement of these 
MMPs in MS has not been described yet. 
The exact source of up regulated ECM components is not very clear. In our 
study we saw induction of TGFβ1 in the chronic inactive and active MS lesions, and 
this is in harmony with  previously published data [Baranzini et al. 2000]. TGFβ1 
stimulates the production of ECM genes/proteins, thereby suggesting that increase in 
TGFβ1 levels in MS patients might induce the expression of ECM components 
involved in the formation of perivascular fibrosis.  
In chronic lesions, the fibrillar collagens were located in the PVS between 
endothelial cells and astrocytic glia limitans. Potential candidates for the production 
of fibrillar collagens are fibroblasts and astrocytes, since at least in vitro astrocytes 
were found to produce fibrillar collagens [Heck et al. 2003]. In vitro we compared the 
ability of fibroblasts and astrocytes to produce fibrillar collagens. The fibroblasts 
were found to be much stronger producer of fibrillar collagens than astrocytes and in 
particular, COL1A1 and COL3A1, which we found to be induced in MS lesions. 
 It has been shown that endothelial cells can produce decorin [Nelimarkka et 
al. 2001], hence it might be possible that decorin in the PVS is being produced by the 
endothelial cells of the vascular basement membrane. We found the up-regulated 
SLRP, biglycan in the perivascular space and also in infiltrating cells in the brain 
parenchyma of active lesions. Macrophages, known producer of biglycan [Schaefer et 
al. 2005] might contribute to this. 
 Since immunostaining results indicated a close interaction between the 
components of the perivascular fibrosis and the infiltrating immune cells, we went on 
to perform in vitro experiments to learn about possible consequences of this 
interaction. Thereby we found that fibrillar collagens reduced the monocytic 
production of CCL2. CCL2 is a potent attractant for monocytes, dendritic cells, 
memory T cells, and basophils and is considered to be a major inflammatory 
chemokine in autoimmune CNS inflammation [Mahad et al. 2003; Huang et al. 
2001]. Since collagen I and III inhibited the production of CCL2 by monocytes, this 
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mechanism might contribute to lesion confinement. This interpretation is supported 
by transfer EAE experiments [Levine 1970], suggesting that reticulin fibers in the 
perivascular space might be linked to vascular blockade and thereby limiting 
infiltration and lesion development. Additional effects of the altered ECM on immune 
cells are expected. For example, biglycan has been reported to be a ligand for TLR2 
and TLR4 in the mouse [Schaefer et al. 2005]. In our study, however, with human 
monocytes biglycan did not stimulate cytokine production (data not shown). It is 
unclear whether the discrepancy of our results and the ones published by Schaefer et 
al are based on species differences or on the exact source of biglycan. Decorin 
absorbs TGFβ and neutralizes its activity thereby acting as a TGFβ scavenger [Iozzo 
1999]. Since TGFβ is a major modulator of autoimmune CNS inflammation, the 
herein described induction of decorin in MS might therefore contribute to lesion 
dynamics [Luo et al. 2007].  
In summary, we have quantified changes in the ECM of MS lesions, identified 
the components of perivascular fibrosis in chronic demyelinated MS lesions, and 
shown that fibrillar collagen I and III inhibit the production of CCL2 by human 
monocytes. There by implying that collagen, I and III in the PVS might function as 
both, a physical and biological barrier limiting immune cell recruitment and lesion 
progression.  
Myelination/remyelination might further be influenced by ECM components 
deposited in the parenchyma. Thrombospondin-1 and -3 might be potential 
candidates. The role of thrombospondins in MS is yet to be established. 
 
Alterations of mediators regulating oligodendrocyte biology in MS lesions 
  ECM provides a substratum upon which cells migrate, proliferate and 
differentiate. Apart from the ECM, growth factors also provide necessary signals for 
cell migration, proliferation, differentiation and survival. In our study we quantified 
different factors known to play a role in the proliferation, differentiation and/or 
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survival of oligodendrocytes, the major myelinating cells of the CNS. The 
composition of these factors might influence the success or failure of remyelination.  
In our experiments, the key factors for differentiation (IGF1, IGF2 and CNTF) 
and proliferation of oligodendrocytes (FGF2 and PDGFAA) were present in the 
demyelinated inactive lesions, which failed to remyelinate.  Among all the regulated 
factors, we were more interested in factors, which were up-regulated in demyelinated 
chronic inactive lesions which failed to remyelinate, because such factors might 
inhibit remyelination. Most striking was the up-regulation of FGF9 in a subset of 
chronically demyelinated lesions, but in none of the remyelinated shadow plaques. 
An alteration of FGF9 in MS lesions has not been described before.  
Neurons can synthesize FGF9 [Garces et al. 2000; Kanda et al. 1999; Kanda 
et al. 2000]. Hence, one reason for the high expression of FGF9 in subset of lesions 
might be the presence of neuronal cell bodies in these particular lesions. Although 
neuronal cell bodies are largely found in the gray matter, they can also occasionally 
be seen in the normal white matter and in white matter MS lesions [Chang et al. 
2008]. Indeed, qPCR showed that those demyelinated lesions with a high FGF9 
content also had a high level of the neuron-specific genes NFL (neurofilament 
protein, light polypeptide) and NFM (neurofilament protein, medium polypeptide). 
To further elucidate whether this is a patient specific or lesion specific phenomenon, 
we analysed additional lesions form one patient expressing higher FGF9 levels. In 
these additional lesions, the expression of FGF9 was similar to control brain, further 
confirming that the increase in FGF9 levels in a subset of demyelinated lesions is a 
lesion specific phenomenon. 
To learn about potential functional implications of the up-regulated FGF9 in 
demyelinated MS lesions, we analysed the effect of exogenous FGF9 on in vitro 
myelination. FGF9 was added to embryonal spinal cord cultures grown on astrocytic 
monolayer. FGF9 inhibited in vitro myelination in a dose dependent manner. This 
decrease in myelination could be due to two reasons: a) decrease in axonal the density 
b) decrease in the number of MOG+ oligodendrocytes (myelinating 
oligodendrocytes). In our experiments, FGF9 did not modulate axonal density, but 
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triggered a decrease in the number of MOG+ cells. This shows that FGF9 inhibited 
oligodendrocyte maturation. This effect of FGF9 on oligodendrocytes can be a direct 
effect or an indirect effect. The myelinating cultures are grown on a monolayer of 
astrocytes, so it might be possible that FGF9 directly effects astrocytes, producing 
secondary factors, possibly inhibiting oligodendrocytes maturation. The observed 
inhibition of in vitro myelination is in harmony with previous study [Cohen et al. 
2000], where FGF9 was shown to alter myelin protein levels during oligodendrocyte 
differentiation. However, another study reported that FGF9 increased the process 
growth in differentiated oligodendrocytes [Fortin et al. 2005]. Future studies 
analyzing effects of FGF9 on pure oligodendrocyte and astrocyte cultures will 
provide further insight into the mechanism of FGF9 mediated inhibition of 
myelination. The presence of FGF9 receptors-FGFR2 and FGFR3 on both 
oligodendrocytes and astrocytes [Fortin et al. 2005]  make both a direct and an 
indirect effect of FGF9 possible. Both FGFR2 and FGFR3 were detected by qPCR in 
MS lesions and in normal brain. In the remyelinated lesions the receptors were ~2 
fold more expressed compared to the demyelinated chronic inactive lesions. This 
increase in transcript levels of the receptors might be contributed by the newly 
recruited OPCs which are involved in the remyelination of the demyelinated lesion.  
Till now only two direct inhibitors of oligodendrocytes are known in relation 
to remyelination failure in MS. These are hyaluronan, a proteoglycan and LINGO1. 
Both hyaluronan and LINGO1 negatively regulate oligodendrocyte maturation and 
hence myelination [Back et al. 2005; Mi et al. 2005]. 
 In summary, this thesis established expression profiles of de- and 
remyelinated MS lesions. This showed the failure of remyelination might not be 
attributed to the absence of one single factor, since factors essential for 
oligodendrocyte maturation, such as IGF1, IGF2, CNTF, FGF2 and PDGFAA were 
still found in demyelinated chronic inactive lesions, which failed to remyelinate. The 
transcript profiling identified an up-regulation of FGF9 in a subset of inactive 
demyelinated lesions. Together, this suggests that up-regulation of FGF9 is one of the 
mechanism contributing to the failure of remyelination in MS.  
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8 Abbreviations  
 
BDNF Brain derived neurotrophic factor 
CNP 2’3’-cyclic nucleotide 3’-phosphodiesterase 
CNTF 
DAB 
Ciliary neurotrophic factor 
3,3’ -diaminobenzidine 
EAE Experimental autoimmune encephalomyelitis 
ECM  Extracellular matrix  
ELISA Enzyme linked immunosorbent assay 
FACS Fluorescence activated cell sorter 
FFPE Formalin fixed paraffin embedded 
FGF Fibroblast growth factor 
GAPDH Glyceraldehydes 3-phosphate dehydrogenase 
H&E Hematoxylin & Eosin 
HFF Human foreskin fibroblast 
IGF Insulin like growth factor 
IL-6 Interleukin-6 
LDA Low density array 
LFB-PAS  Luxol fast blue- periodic acid schiffs 
LIF Leukemia inhibitory factor 
MAG Myelin associated glycoprotein 
MBP Myelin basic protein 
MMP Matrix metalloproteinases 
MOG Myelin oligodendrocyte glycoprotein 
MS 
NAWM 
Multiple sclerosis 
Normal appearing white matter 
NFL Neurofilament protein, light polypeptide 
NFM Neurofilament protein, medium polypeptide 
NGF Nerve growth factor 
NRG Neuregulins 
NT-3 
O/N 
Neurotrophin-3 
Over night 
OPC Oligodendrocyte glycoprotein  
ORO Oil red O 
PBS Phosphate buffer saline 
PDGF Platelet derived growth factor 
PLP Proteolipid protein 
PPIA Cyclophilin A 
PRMS Progressive-relapsing multiple sclerosis 
PSA-NCAM Polysialylated neural cell adhesion molecule 
RRMS 
RT 
Relapsing-remitting multiple sclerosis 
Room temperature 
SLRP Small leucine rich proteoglycan 
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SMI-31 
SPMS 
TIMP 
cpm 
h 
min 
qPCR 
rpm 
Neurofilament phosphorylated epitope 
Secondary progressive multiple sclerosis 
Tissue inhibitor of matrix metalloproteinases 
Counts per minute 
Hours 
Minutes 
Quantative polymerase chain reaction 
Rotations per minute 
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